

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

**The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study): study protocol for a randomized, parallel, open-label, intervention study comparing different approaches to dietary self-management in patients with type 1 diabetes**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029859
Article Type:	Protocol
Date Submitted by the Author:	15-Feb-2019
Complete List of Authors:	Ewers, Bettina; Steno Diabetes Center Copenhagen, Nutrition and Food Services Department Vilsboell, Tina; Steno Diabetes Center Copenhagen; Kobenhavns Universitet, Department of Clinical Medicine, Faculty of Health and Medical Sciences Andersen, Henrik; Steno Diabetes Center Copenhagen Bruun, Jens; Steno Diabetes Center Aarhus, Aarhus, Denmark; University of Aarhus, Department of Clinical Medicine
Keywords:	Randomized controlled trial, Type 1 diabetes, Carbohydrate counting, Basic carbohydrate counting, Advanced carbohydrate counting, Nutritional education

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study): study protocol for a  
5 randomized, parallel, open-label, intervention study comparing different approaches to dietary self-  
6 management in patients with type 1 diabetes  
7  
8  
9

10  
11  
12 Bettina Ewers,<sup>1</sup> Tina Vilsboell,<sup>1,2</sup> Henrik Ullits Andersen,<sup>1</sup> Jens Meldgaard Bruun,<sup>3,4</sup>  
13  
14

15  
16  
17 <sup>1</sup>Steno Diabetes Center Copenhagen, Gentofte, Denmark.  
18

19 <sup>2</sup>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen,  
20 Denmark.  
21

22 <sup>3</sup>Steno Diabetes Center Aarhus, Aarhus, Denmark.  
23

24 <sup>4</sup>Department of Clinical Medicine, University of Aarhus, Denmark.  
25  
26  
27

28  
29 **Correspondence to** Bettina Ewers, [bettina.ewers@regionh.dk](mailto:bettina.ewers@regionh.dk) or +45 30912997  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Clinical guidelines recommend that patients with type 1 diabetes (T1D) learn carbohydrate counting or similar methods to improve glycaemic control. Although, systematic educating in carbohydrate counting is still not offered as standard-of-care for all patients on multiple daily injections (MDI) therapy in outpatient diabetes clinics in Denmark. This may be due to the lack of evidence as to which educational methods are the most effective for training patients in carbohydrate counting. The objective of this study is to compare the effect of two different educational programs in carbohydrate counting with the usual dietary care on glycaemic control in patients with T1D.

**Methods and analysis:** The study is designed as a randomized, controlled trial with a parallel-group design. The total study duration is 12 months with data collection at baseline, 6 and 12 months. We plan to include 231 Danish adult patients with T1D. Participants will be randomized to one of three dietician-led interventions; 1) A program in basic carbohydrate counting, 2) A program in advanced carbohydrate counting including an automated bolus calculator or 3) Usual dietary care. The primary outcome is changes in glycated haemoglobin A1c (HbA1c) or mean amplitude of glycaemic excursions (MAGE) from baseline to end of the intervention period (week 24) between and within each of the three study groups. Other outcome measures include changes in other parameters of plasma glucose variability (e.g. time in range), body weight and composition, lipid profile, blood pressure, mathematical literacy skills, carbohydrate estimation accuracy, dietary intake, diet-related quality of life, perceived competencies in dietary management of diabetes and perceptions of an autonomy supportive dietician-led climate, physical activity and urinary biomarkers.

**Ethics and dissemination:** The protocol has been approved by the Ethics Committee of the Capital Region, Copenhagen, Denmark.

**Registration:** The trial protocol is registered on ClinicalTrials.gov NCT03623113.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Strengths and limitations of this study**

1. The study has a long-term follow-up and will provide knowledge on the effects of different levels of carbohydrate counting
2. The study applies well-documented measures of glycaemic control as effect-parameters
3. The results obtained have applicability beyond Denmark and has the potential to be included in the recommendations in future guidelines
4. One significant limitation is the lack of a dietary untreated control group

## Introduction

Carbohydrate is the nutrient in our diet with by far the highest impact on plasma glucose levels. The total amount of carbohydrates consumed in a meal is the major predictor of the postprandial glucose response. Thus, monitoring dietary intake of carbohydrates is important to control postprandial glucose fluctuations, which may lead to clinical benefits such as a reduction in glucose variability, an improvement of glycated haemoglobin A1c (HbA1c), and a reduction in diabetes-related complications.

Clinical guidelines in medical nutrition therapy recommend that patients with type 1 diabetes (T1D) learn carbohydrate counting or similar experience-based methods to improve glycaemic control (1-4). Two levels of carbohydrate counting have been defined internationally with different learning objectives and increasing complexity; a basic and an advanced level (5, 6). Basic carbohydrate counting (BCC) includes understanding of the relationship between food, physical activity, and plasma glucose levels with special attention on consistency in the timing, type, amount and distribution of carbohydrate-containing foods consumed. Advanced carbohydrate counting (ACC) is targeting the patient who masters BCC, who is on intensive insulin therapy and is prepared to learn how to adjust insulin according to carbohydrate intake. In the clinical guidelines and studies, the term “carbohydrate counting” is often used synonymously with ACC, while the sole effect of BCC on glycaemic control is largely unknown. Systematic reviews and meta-analyses of randomized controlled trials (RCTs) have shown that ACC can reduce HbA1c by up to 7 mmol/mol in adults with poorly controlled T1D (7-9). Despite this, systematic educating and training is still not offered routinely for patients on multiple daily insulin injections (MDI) therapy in outpatient clinics in Denmark. This may be due to the lack of evidence as to which educational methods are the most effective for training patients in carbohydrate counting in terms of supporting patients in implementation and ongoing adherence to the use of carbohydrate counting as a tool for meal planning in their daily life for improving glycaemic control.

Ideally, patients with T1D treated on MDI therapy need to be able to manage the following steps of calculation when using carbohydrate counting: 1) Correct calculation of the total carbohydrate content in each meal according to portion sizes of each carbohydrate containing food item (equal to BCC) and 2) Correct calculation of insulin dose according to the amount of carbohydrates to be consumed using a carbohydrate-to-insulin ratio, an insulin sensitivity factor, and the current and target plasma glucose (equal to ACC). In other words, patients with diabetes need to have sufficient mathematical literacy skills, including numeracy skills, to be able to practice the above-mentioned steps several times each day. Recent studies suggest that lower literacy and numeracy skills are associated with poorer portion size estimation, understanding of food labels, diabetes-related self-management abilities, diabetes control and increased body mass index (BMI) (10-16). Other studies have found that patients with diabetes frequently assess their intake of carbohydrates inaccurately and this has been associated with a poorer HbA1c (17-19). Particularly mixed meals, high-calorie foods, and larger portion sizes resulted in inaccurate carbohydrate estimation. One study also found that underestimation of carbohydrate-rich meals was associated with higher daily plasma glucose variability in adults with T1D (20). Thus, assessment of numeracy skills is highly relevant to ensure that a nutritional education programs address patients with low literacy and numeracy. This may be done by numeracy-focused educational exercises and materials or hands-on learning.

Recent years technological innovations including applications (apps) for smartphones have been introduced to reduce the complexity of carbohydrate counting and possibly compensate for poor numeracy skills. So far, no technological devices can replace the patients' self-estimations of the carbohydrate content in most meals e.g. in mixed meals (addressing step 1). RCTs have demonstrated that ACC supported by the use of automated bolus calculator (ABC) software to assist insulin dose decision making (addressing step 2) compared to

1  
2  
3  
4 unassisted ACC significantly improves HbA1c and treatment satisfaction in patients with T1D treated with  
5 MDI (21-23). However, a recent exploratory study found that lower numeracy skills were associated with  
6 smaller reductions in HbA1c after a 12-month education program in ACC with no benefit from the use of an  
7 ABC compared to manual calculations (24). These findings support the need for more intensified dietary  
8 education in BCC before learning ACC. Additionally, the concept of ACC may not be useful in all patients  
9 with T1D on MDI therapy because of potential patient barriers, lack of motivation to learn the method, and  
10 low levels of education, literacy or numeracy skills. Other barriers include lack of appropriate learning  
11 environments to promote behavioural change and availability of trained dietitians to facilitate the learning  
12 process (25). In a study of patients with diabetes perceived competence was predicted by the degree to which  
13 the patients experienced the health-care climate to be autonomy supportive, and perceived competence at  
14 carrying out the treatment in turn predicted HbA1c (26). Group-based approaches with practised-focused  
15 dietary education compared to individual dietary counselling has been practiced in some settings but are under-  
16 investigated (27). In line with this we are currently carrying out a RCT based on this protocol.  
17  
18  
19  
20  
21

## 22 **Aim**

23 The aims are to examine the effectiveness of two different group-based dietitian-led practise-focused  
24 educational approaches for dietary self-management compared to the standard nutrition education on  
25 glycaemic control in patients with T1D. The BCC concept aims at improving carbohydrate counting accuracy  
26 and day-to-day consistency of carbohydrate intake (the BCC intervention) and the concept of ACC aim at  
27 improving prandial insulin dose accuracy using an automated bolus calculator (the ABC-ACC intervention).  
28  
29  
30  
31

## 32 **Methods and analysis**

### 33 **Study design**

34 The study is as a randomized controlled intervention trial with a parallel-group design (see figure 1).  
35  
36

37 For each participant the study duration is 48 months and includes up to seven visits at the study site (see figure  
38 2). All participants will be instructed to maintain their habitual lifestyle in all other aspects than their diet, e.g.  
39 keeping the same level of physical activity during the study period. All participants will be instructed to follow  
40 their regular diabetes care in the hospital, which usually includes four yearly visits with a diabetologist  
41 (endocrinologist) and one yearly consultation with a diabetes nurse. Participants will be instructed not to  
42 receive any further dietary education during the study period. Close relatives can participate in the dietary  
43 education in all three study groups if the participant needs support to manage dietary changes.  
44  
45

46 The study flow is presented in figure 3. The study follows the guidelines of Standard Protocol Items for  
47 Randomized Trials (SPIRIT).  
48  
49

### 50 **Setting**

51 The study will be carried out in the outpatient clinic at Steno Diabetes Center Copenhagen (SDCC) in Gentofte,  
52 Denmark.  
53

### 54 **Recruitment and consent**

55 As a temporary supplementary treatment initiative, SDCC offers courses in BCC and ABC-ACC for all  
56 patients with T1D treated in the capital region of Denmark. Participants for the current study will be recruited  
57 among patients signing up for these courses or patients directly referred to one of the courses or the study by  
58  
59  
60

1  
2  
3  
4 a health care professional (diabetologist, diabetes nurse or dietitian) from SDCC or from a Steno Partner  
5 hospital in the capital region. A course administrator at SDCC will contact all interested or referred patients  
6 by telephone and provide information about the study. In addition, potential study participants will be recruited  
7 through information on sdcc.dk and other electronic media or patient-related networks. If the patient is  
8 interested in the study, the patient will receive the written patient information by mail or e-mail. If interested  
9 in study participation, the study investigator/study personnel will schedule a personal meeting for oral patient  
10 information, offering the possibility of bringing a confidant. The patient will be given time to discuss any  
11 questions and will be informed that he/she has at least 24 hours to decide on participation in the study. If the  
12 patient decides to participate in the study, the patient and the study investigator/study personnel will sign the  
13 written informed consent, and the investigator/study personnel will perform a screening. If all inclusion criteria  
14 are fulfilled and none of the exclusion criteria are met, the patient will be included in the study and randomised  
15 to one of three groups. Patients who decline to participate or do not meet the inclusion criteria will continue  
16 their usual care in an outpatient diabetes clinic and will be offered to participate on a BCC or ACC course if  
17 they still wish to do so. Participants will be informed that participation is voluntary, and that they may withdraw  
18 their consent at any time.  
19  
20  
21  
22  
23

#### 24 Inclusion criteria

25 Patients with T1D between 18-75 years of age with a diabetes duration above 12 months and with an initial  
26 HbA1c of 53-97 mmol/mol on MDI therapy with a basal-bolus insulin regime are eligible for the study.  
27  
28

#### 29 Exclusion criteria

30 Patients are excluded if they have other types of diabetes than T1D, are practicing carbohydrate counting as  
31 judged by the investigator, have a low daily intake of carbohydrates (defined as below 25 E% or 100 g/day),  
32 have participated in a BCC group program within the last two years, use an insulin pump or plan to have an  
33 insulin pump within the study period, use a fixed dose of rapid acting insulin therapy for meals, use split-mixed  
34 insulin therapy, use an open CGM or plan to have an open CGM within the study period, use an automated  
35 bolus calculator, have gastroparesis, have uncontrolled medical issues affecting the dietary intake as judged  
36 by the investigator or a medical expert. Women who are pregnant or breastfeeding or have plans of pregnancy  
37 within the study period are also excluded. Furthermore, patients who are either participating in other clinical  
38 studies or are unable to understand the informed consent and the study procedures will be excluded.  
39  
40  
41  
42  
43

#### 44 Randomization

45 Participants eligible for inclusion in the study will be randomly allocated in a 1:1:1 ratio to one of the three  
46 groups (BCC, ABC-ACC or control) using a computer-generated randomization in the software program  
47 *REDCap*. The randomization is done by stratifying participants based on sex and HbA1c at baseline. The  
48 randomization is done in blocks in to order to ensure an equal number of participants in each group.  
49  
50

#### 51 Intervention groups

52 The BCC program consists of two sessions of three hours and a follow-up group session of two hours. The  
53 BCC program uses trained dietitians following a planned curriculum which include experience-based learning  
54 with problem-solving exercises, hands-on activities, short theoretical presentations, discussions of  
55 motivational aspects and coping strategies. The BCC program integrates peer modelling, skills development,  
56 goal setting, observational learning and social support into the program content and activities. The training  
57 includes identifying carbohydrates in food, reading carbohydrate tables, calculating the carbohydrate content  
58  
59  
60



1  
2  
3  
4 from food labels, tables and apps and use of a personalized carbohydrate plan with guiding suggestions for  
5 daily intake of carbohydrates at meals based on 4-days of personal dietary recording performed before the  
6 program including plasma glucose measurements and prandial insulin dosages taken. An app (*Diabetes og*  
7 *Kulhydrattælling*®. The Danish Diabetes Association, Pragma soft A/S, available in Google Play® and  
8 AppStore®) will be introduced to support estimation and calculation of carbohydrates and assist in simple  
9 insulin dose determination if participants choose to consume more carbohydrates at a meal than suggested in  
10 their personal carbohydrate plan.  
11  
12

13  
14 The ABC-ACC program consists of a 4-hour group session and two individual follow-up sessions (two 45-  
15 minutes sessions). The program uses trained dietitians with supervision by a medical doctor and follows a  
16 planned curriculum. The ABC-ACC intervention is a group-based educational program based on the well-  
17 described BolusCal concept (28). The program includes fast training in BCC, ACC and bolus calculation using  
18 an automated bolus calculator (*mySugr Pro*®. Roche, available in Google Play® and AppStore®) taking insulin  
19 onboard, insulin sensitivity factor and differentiated carbohydrate-to-insulin ratios during the day into account.  
20 The carbohydrate-to-insulin ratios are based on 7-days of personal dietary recording including plasma glucose  
21 measurements and prandial insulin dosages taken. The ABC-ACC program contains theoretical and practical  
22 training. The teaching is based on theory and examples from everyday life with T1D and the educators help  
23 the participants with their specific diabetes-related problems and try to find appropriate practical solutions  
24 together with the participant.  
25  
26

### 27 Control group

28 Participants randomized to the control group receive current standard outpatient nutrition education in T1D.  
29 This includes individual guidance by a trained dietitian, with one initial 60 minutes dietary counselling session  
30 and two individual 30 minutes follow-up session. The individual guidance is based on the overall treatment  
31 goal and the defined personal dietary goals for behavioural change according to patient preferences. Dietary  
32 guidance includes topics such as carbohydrate sources (e.g. practicing glycaemic index and dietary fibre  
33 intake) and amounts of carbohydrates or more general dietary recommendations according to patient needs.  
34  
35  
36

### 37 Data collection

38 All study data will be collected at the three visits with clinical examination (baseline, after 6 and 12 months).  
39 Data will be obtained from a self-reported patient questionnaire, electronic medical records and the physical  
40 examinations conducted by the study investigator or study personnel. All questionnaire data will be collected  
41 electronically using the software system *REDCap* according to local standards for research projects in the  
42 capital region of Denmark. In addition, all sources will be registered in this database. Data generated and stored  
43 for specific equipment (e.g. Dual-energy-X-ray absorptiometry (DXA) data stored in the DXA scanner  
44 software database), electronic medical data (blood and urine measurements, glucose- and lipid-lowering  
45 medicine), data from iPro®2 CGM using software from Medtronic (Northridge, CA, US) to download CGM  
46 measurements, dietary data on total energy and nutrients based calculations from the software system *Vitakost*  
47 will be added to the database in *REDCap* on an ongoing basis and at the end of study.  
48  
49  
50

51 The primary outcome is the difference in mean HbA1c or MAGE from baseline to end of the intervention  
52 (week 24) between and within each of the three study groups (BCC, ABC-ACC and control).  
53

54 A schematic overview of outcomes measurements is presented in table 1.  
55  
56  
57  
58  
59  
60

Table 1. Schematic overview of outcomes measured

Week no from start of intervention	-4 to -1	12	24	48
HbA1c	X	X	X	X
Plasma lipids	X		X	X
Body weight	X		X	X
Height	X			
Waist and hip circumference	X		X	X
Blood pressure	X		X	X
Blood samples, fasting	X		X	X
Urine samples for 4 days	X		X	
Glucose variability (CGM) including PG diary for 6 days	X		X	
Body composition (DXA)	X		X	
Prescribed lipid- and glucose lowering medication	X		X	X
F: Dietary registration for 4 days	X		X	
Q: Diet-related quality of life	X		X	X
Q: Perceived Competencies in Diabetes	X		X	X
Q: Health-Care Climate	X		X	
Q: Carbohydrate estimation accuracy	X		X	X
Q: Mathematical literacy	X		X	X
Q: Demographic data	X			
Q: Physical activity	X		X	X

Abbreviations CGM=continuous glucose monitoring d=day; DXA=Dual-energy-X-ray absorptiometry; F=forms; PG=plasma glucose; Q=Questionnaire.

Secondary outcomes are listed below:

*Clinical parameters:* Body weight, body composition (measured by DXA), waist and hip circumference blood pressure, type and dose of prescribed glucose- and lipid lowering medication, other parameters of plasma glucose variability including time in range (3.9-10.0 mmol/l), % time spent in hypoglycaemia (<3.9 mmol/l), % time spent in hyperglycaemia (e.g. >10.0 mmol/l) and standard deviation of mean plasma glucose assessed from CGM measurements.

*Blood and urine samples:* HbA1c (after 12 and 48 weeks), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, total cholesterol, free fatty acids and triglycerides, alanine aminotransferase (ALAT), urine albumin/creatinine ratio and urinary biomarkers based on three daily midstream urine spots collected for four days.

*Patient-reported outcomes:* Diet-related quality of life, perceived competencies in diabetes, health-care climate, carbohydrate estimation accuracy, mathematical literacy skills, physical activity and demographic questions. The six questionnaires used are:

*Diabetes diet-related quality of life questionnaire (DDRQOL):* The DDRQOL is a scale which has been validated in patients with diabetes (29). The scale is designed to determine the quantitative and qualitative satisfaction with diet and the degree of restriction of daily life and social life functions due to the dietary changes. A forward translation and cultural adaption of the DDRQOL was done by a Japanese-Danish interpreter with a background as a clinical dietitian and an expert panel of six clinical dietitians working with diabetes. This was followed by a pilot testing by 10 patients.

*Perceived Competencies in Diabetes Scale (PCS):* The PCS includes four items that reflect participants' feelings of competence about engaging in a healthier behaviour and participating in a nutritional education

1  
2  
3  
4 program. Forward and backward linguistic translation from English to Danish has been done according to  
5 standard procedures in 2001 under the guidance of Professor Vibeke Zoffmann.  
6

7 *Health-Care Climate Questionnaire (HCCQ)*: The HCCQ chosen in this study is a 5-item short form of the  
8 original 15-item measure that assesses patients' perceptions of the degree to which dieticians are autonomy  
9 supportive versus controlling in providing dietary treatment.  
10

11  
12 *Carbohydrate photographic questionnaire (CPQ)*: The CPQ is an electronic questionnaire assessing diabetes  
13 patients' abilities to estimate portion sizes of 11 commonly eaten high-carbohydrate foods correctly. The CPQ  
14 has been developed and validated against real food in 87 patients with T1D. A manuscript of these study results  
15 has been submitted (Ewers et al, unpublished).  
16

17  
18 *Mathematical literacy questionnaire*: A 10-item test with modified questions from the nutrition domain of the  
19 *Diabetes Numeracy Test (DNT)* (30) was designed and feasibility tested to investigate mathematical literacy  
20 including numeracy skills (addition, subtraction, division and multiplication) which are essential for  
21 understanding numbers and applying mathematical skills in daily life e.g. for calculating carbohydrates.  
22

23  
24 *International Physical Activity Questionnaire Short Form (IPAQ SF)*: The Danish version of the IPAQ SF (31)  
25 will be used to assess changes in level of physical activity during the study period.  
26

27  
28 Self-reported demographic questions include level of education, occupation, marital status, household  
29 composition and yearly income.  
30

31 *Dietary data*: Four days of weighed dietary food records collected at baseline and six months after baseline.  
32 Dietary records will be calculated using the software system *Vitakost* (Vitakost Aps, Kolding) where nutrient  
33 and energy calculations are based on the Danish national food database. The dietary food records are used to  
34 estimate total energy intake (kJ/d), intake of carbohydrates, protein and fat (g/day and g/meal), added sugar  
35 (g/d) and total dietary fibre intake (g/d).  
36

37  
38 *Baseline data (from the electronic medical record)*: type of diabetes, gender, age, smoking status, medical  
39 conditions, total number of visits at a diabetologist and diabetes nurse and dietician during the study period.  
40

#### 41 Data analysis plan

42 The trial is ongoing. The patient recruitment started in October 2018 and is expected to be completed by  
43 October 2021.  
44

#### 45 Sample size calculation

46 A power calculation was conducted based on the primary outcome measures HbA1c and MAGE. Allowing  
47 for an estimated drop-out rate of 20% and subgroup analyses the sample size was planned to include a total of  
48 231 patients in the study (77 in each arm). This was based on a sample size calculation which suggested that  
49 including 64 participants in each of the study groups would give 80% power to detect a clinically meaningful  
50 difference in change in HbA1c of 3.5 mmol/mol between the BCC group versus the control group or the ABC-  
51 ACC group versus the control group with a 5% significance level using a two-sided test and an estimated  
52 standard deviation (SD) of 7 mmol/mol. This SD has previously been used for sample size calculations in ACC  
53 trials (21) and was similar to what was found in an evaluation of previous conducted BCC courses at SDCC  
54 on mean changes and SD of HbA1c after 6 months among completers with T1D (n=185). MAGE has only  
55 been used as an outcome measure of glucose variability in a few randomized controlled dietary intervention  
56  
57  
58  
59  
60

1  
2  
3  
4 studies of patients with diabetes (32, 33) showing differences in changes in MAGE up to 4.8 mmol/l (SD: 1.0)  
5 after a 12-week carbohydrate counting intervention (32), but is regularly used in other clinical studies  
6 evaluating glucose variability . By including 77 participants in each study group we will have a power of 80%  
7 (alpha level of 0.05) in a two-sided test to detect a clinically meaningful difference in the change in MAGE  
8 during the intervention period (week 24) of  $\geq 0.35$  mmol/l (SD 0.7 mmol/l) between the study groups.  
9  
10

## 11 12 13 Statistical methods

14 Analysis and reporting of the study results will follow the CONSORT (Consolidated Standards of Reporting  
15 Trials) guidelines for reporting parallel group randomised trials (34). Results will be presented as means (SD)  
16 for normally distributed variables and as medians (inter-quartile range) for non-normally distributed variables.  
17 Parametric tests (general linear models) will be used to test differences in outcomes from baseline to follow-  
18 up. If model assumptions cannot be met even after logarithmic transformation, non-parametric tests will be  
19 used. Plots of residuals versus predicted values will be used to judge normality.  
20  
21

22 The baseline demographics as well as clinical and diabetes-related characteristics of the intervention and the  
23 control groups will be presented and compared. The average changes between baseline and week 24 and 48 in  
24 primary and secondary outcomes will be calculated for each of the three groups. Intention-to-treat (ITT)  
25 analysis will be performed as the primary analysis on all primary and secondary outcomes after the last  
26 participant has ended participation. Missing values will be handled with a last observation carried forward  
27 approach for ITT analysis. Per-protocol (PP) analysis will only be performed in case of sensitivity testing.  
28 Metabolic patterns will be tested with multivariate statistics. Adjustment for relevant confounders will be  
29 performed. Heterogeneity in responsiveness to the interventions will be tested by dividing each intervention  
30 group into smaller groups based on data distribution (medians) or clinically meaningful cut-points. Two-sided  
31 tests will be used. *P* values of  $< 0.05$  are considered significant. The statistical programs SPSS and SAS will  
32 be used for data analysis.  
33  
34  
35

## 36 37 Ethics and dissemination

38 The study will be conducted in accordance with the ethical principles in the Declaration of Helsinki and to the  
39 regulations for Good Clinical Practice (GCP) to the extent that this is relevant for non-medical studies. The  
40 study has been approved by the Ethics Committee of the Capital Region, Copenhagen (#H-18014897), has  
41 been approved for data storage by the Danish Data Protection Agency (journal no VD-2018-124, I-suite no  
42 6367) and has been registered at ClinicalTrials.gov (NCT03623113).  
43  
44

45 All health-related matters and sensitive personal data will be handled in accordance with the Danish “Act on  
46 Processing of Personal Data”. All health-related matters and sensitive personal data (blood test results etc.)  
47 will be depersonalized. All participants will be given a study number referring to their personal information,  
48 which will be stored securely and separately. Data will be stored in coded form for 10 years after last participant  
49 has attended the last visit, after which the data will be fully anonymised.  
50  
51

52 Data is owned by the investigators who are responsible for publishing the results. Positive and negative as well  
53 as inconclusive study results will be published by the investigators in international peer-reviewed journals, and  
54 all co-authors must comply with the Vancouver rules. BE will be responsible for writing the first draft of the  
55 manuscript based on the main study results as a first author under guidance by TV and JMB. The study results  
56 will be presented at relevant national and international scientific conferences and meetings and will be  
57 published in international peer-reviewed scientific journals.  
58  
59  
60

## References

1. Kliniske retningslinjer for behandling af voksne med Type 1 diabetes. Sundhedsstyrelsen (Danish Health & Medicines Authority), Copenhagen; 2010.
2. Rammeplan for diætbehandling af type 1 diabetes Foreningen af kliniske diætister (The association of clinical dietitians); 2011.
3. Mann JI, De Leeuw I, Hermansen K, Karamanos B, Karlstrom B, Katsilambros N, et al. Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2004;14(6):373-94.
4. Sheard NF, Clark NG, Brand-Miller JC, Franz MJ, Pi-Sunyer FX, Mayer-Davis E, et al. Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the american diabetes association. *Diabetes Care*. 2004;27(9):2266-71.
5. Gillespie SJ, Kulkarni KD, Daly AE. Using carbohydrate counting in diabetes clinical practice. *J Am Diet Assoc*. 1998;98(8):897-905.
6. Kulkarni K. Carbohydrate Counting: A Practical Meal-Planning Option for People With Diabetes. *Clinical Diabetes*. 2005;23(5):120-2.
7. Bell KJ, Barclay AW, Petocz P, Colagiuri S, Brand-Miller JC. Efficacy of carbohydrate counting in type 1 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol*. 2014;2(2):133-40.
8. Fu S, Li L, Deng S, Zan L, Liu Z. Effectiveness of advanced carbohydrate counting in type 1 diabetes mellitus: a systematic review and meta-analysis. *Sci Rep*. 2016;6:37067.
9. Schmidt S, Schelde B, Norgaard K. Effects of advanced carbohydrate counting in patients with type 1 diabetes: a systematic review. *Diabet Med*. 2014;31(8):886-96.
10. Bowen ME, Cavanaugh KL, Wolff K, Davis D, Gregory B, Rothman RL. Numeracy and dietary intake in patients with type 2 diabetes. *Diabetes Educ*. 2013;39(2):240-7.
11. Cavanaugh K, Huizinga MM, Wallston KA, Gebretsadik T, Shintani A, Davis D, et al. Association of numeracy and diabetes control. *Ann Intern Med*. 2008;148(10):737-46.
12. Huizinga MM, Beech BM, Cavanaugh KL, Elasy TA, Rothman RL. Low numeracy skills are associated with higher BMI. *Obesity (Silver Spring)*. 2008;16(8):1966-8.
13. Huizinga MM, Carlisle AJ, Cavanaugh KL, Davis DL, Gregory RP, Schlundt DG, et al. Literacy, numeracy, and portion-size estimation skills. *Am J Prev Med*. 2009;36(4):324-8.
14. Marden S, Thomas PW, Sheppard ZA, Knott J, Lueddeke J, Kerr D. Poor numeracy skills are associated with glycaemic control in Type 1 diabetes. *Diabet Med*. 2012;29(5):662-9.
15. Rothman RL, DeWalt DA, Malone R, Bryant B, Shintani A, Crigler B, et al. Influence of patient literacy on the effectiveness of a primary care-based diabetes disease management program. *JAMA*. 2004;292(14):1711-6.
16. Rothman RL, Housam R, Weiss H, Davis D, Gregory R, Gebretsadik T, et al. Patient understanding of food labels: the role of literacy and numeracy. *Am J Prev Med*. 2006;31(5):391-8.
17. Bishop FK, Maahs DM, Spiegel G, Owen D, Klingensmith GJ, Bortsov A, et al. The Carbohydrate Counting in Adolescents With Type 1 Diabetes (CCAT) Study. *Diabetes Spectrum*. 2009;22(1):56-62.
18. Mehta SN, Quinn N, Volkening LK, Laffel LM. Impact of carbohydrate counting on glycemic control in children with type 1 diabetes. *Diabetes Care*. 2009;32(6):1014-6.
19. Smart CE, Ross K, Edge JA, King BR, McElduff P, Collins CE. Can children with Type 1 diabetes and their caregivers estimate the carbohydrate content of meals and snacks? *Diabet Med*. 2010;27(3):348-53.
20. Brazeau AS, Mircescu H, Desjardins K, Leroux C, Strychar I, Ekoe JM, et al. Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes. *Diabetes Res Clin Pract*. 2013;99(1):19-23.
21. Hommel E, Schmidt S, Vistisen D, Neergaard K, Gribhild M, Almdal T, et al. Effects of advanced carbohydrate counting guided by an automated bolus calculator in Type 1 diabetes mellitus (StenoABC): a 12-month, randomized clinical trial. *Diabet Med*. 2017;34(5):708-15.



- 1  
2  
3  
4 22. Schmidt S, Meldgaard M, Serifovski N, Storm C, Christensen TM, Gade-Rasmussen B, et al.  
5 Use of an automated bolus calculator in MDI-treated type 1 diabetes: the BolusCal Study, a randomized  
6 controlled pilot study. *Diabetes Care*. 2012;35(5):984-90.
- 7 23. Ziegler R, Cavan DA, Cranston I, Barnard K, Ryder J, Vogel C, et al. Use of an insulin bolus  
8 advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal  
9 glycemic control: first results from the ABACUS trial. *Diabetes Care*. 2013;36(11):3613-9.
- 10 24. Schmidt S, Vistisen D, Almdal T, Hommel E, Norgaard K. Exploring factors influencing  
11 HbA1c and psychosocial outcomes in people with type 1 diabetes after training in advanced carbohydrate  
12 counting. *Diabetes Res Clin Pract*. 2017;130:61-6.
- 13 25. Kawamura T, Takamura C, Hirose M, Hashimoto T, Higashide T, Kashihara Y, et al. The  
14 factors affecting on estimation of carbohydrate content of meals in carbohydrate counting. *Clin Pediatr*  
15 *Endocrinol*. 2015;24(4):153-65.
- 16 26. Williams GC, Freedman ZR, Deci EL. Supporting autonomy to motivate patients with  
17 diabetes for glucose control. *Diabetes Care*. 1998;21(10):1644-51.
- 18 27. Toft U, Kristoffersen L, Ladelund S, Ovesen L, Lau C, Pisinger C, et al. The effect of adding  
19 group-based counselling to individual lifestyle counselling on changes in dietary intake. The Inter99 study--a  
20 randomized controlled trial. *Int J Behav Nutr Phys Act*. 2008;5:59.
- 21 28. Meldgaard M, Damm-Frydenberg C, Vesth U, Norgaard K, Schmidt S. Use of advanced  
22 carbohydrate counting and an automated bolus calculator in clinical practice: the BolusCal® training  
23 concept. *International Diabetes Nursing*. 2015;12:8-13.
- 24 29. Sato E, Suzukamo Y, Miyashita M, Kazuma K. Development of a diabetes diet-related  
25 quality-of-life scale. *Diabetes Care*. 2004;27(6):1271-5.
- 26 30. Huizinga MM, Elasy TA, Wallston KA, Cavanaugh K, Davis D, Gregory RP, et al.  
27 Development and validation of the Diabetes Numeracy Test (DNT). *BMC Health Serv Res*. 2008;8:96.
- 28 31. Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity  
29 Questionnaire Short Form (IPAQ-SF): a systematic review. *Int J Behav Nutr Phys Act*. 2011;8:115.
- 30 32. Bell KJ, Gray R, Munns D, Petocz P, Steil G, Howard G, et al. Clinical Application of the  
31 Food Insulin Index for Mealtime Insulin Dosing in Adults with Type 1 Diabetes: A Randomized Controlled  
32 Trial. *Diabetes Technol Ther*. 2016;18(4):218-25.
- 33 33. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, et al.  
34 Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. *Am J*  
35 *Clin Nutr*. 2015;102(4):780-90.
- 36 34. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT  
37 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*.  
38 2010;340:c869.
- 39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Patient and public involvement:** Patients were involved in developing the educational content of the  
5 program in basic carbohydrate counting. Patients were not involved in setting the research questions or the  
6 outcome measures, nor were they involved in developing the study design. Information may be disseminated  
7 to the general public via any media coverage of study findings.  
8  
9

10 **Authors' contributions:** BE conceived the original idea for this trial, planned the study design, performed  
11 the sample size calculations and wrote the first draft of the protocol manuscript. TV and JMB provided valuable  
12 input regarding trial design, planning and analytical considerations, and edited the first draft of the protocol  
13 manuscript. HUA has contributed intellectually to the protocol. All authors approved the final version of the  
14 clinical trial protocol. BE is the principle investigator and is responsible for correspondence with all authorities  
15 regarding the study and is responsible for the data collection (recruitment, screening and clinical study  
16 examinations), overall monitoring the trial and for conducting the statistical analyses. TV, JMB and HUA are  
17 supervisors and coinvestigators of this trial. Should any safety concerns arise during the conduct of the study  
18 these will be brought to the attention of HUA, TV and JMB by BE and will carefully reviewed.  
19  
20  
21

22 **Funding statement:** This work was supported by The Beckett Foundation (grant number 17-2-0957), the  
23 Axel Muusfeldts Foundation (grant no 2017-856) and the Novo Nordisk Foundation (No assigned grant  
24 number) as part of a supplementary treatment initiative at SDCC in 2018-2020.  
25  
26

27 **Competing interests:** None of the authors have financial relationships with organizations that might have  
28 an interest in the submitted work, or other relationships or activities that could appear to have influenced the  
29 submitted work.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Figure titles and legends (captions)**  
5  
6  
7

8 **Figure 1.** Study design  
9

10  
11 **Figure 2.** Schematic diagram of the intervention  
12

13  
14 BCC, basic carbohydrate counting; ABC-ACC, advanced carbohydrate counting with an automated bolus  
15 calculator; BP, blood pressure; BW, body weight; CGM, Continuous Glucose Monitoring; DXA, dual-energy-  
16 X-ray absorptiometry; V, visit; WHC, waist-hip circumference.  
17

18  
19 **Figure 3.** Study flow diagram. The planned flow of participants through the stages of the study  
20

21  
22 BCC, basic carbohydrate counting; ABC-ACC, advanced carbohydrate counting with an automated bolus  
23 calculator.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Study design

207x49mm (120 x 120 DPI)




Figure 2. Schematic diagram of the intervention.

BCC, basic carbohydrate counting; ABC-ACC, advanced carbohydrate counting with an automated bolus calculator; BP, blood pressure; BW, body weight; CGM, Continuous Glucose Monitoring; DXA, dual-energy-X-ray absorptiometry; V, visit; WHC, waist-hip circumference.

218x162mm (120 x 120 DPI)




Figure 3. Study flow diagram. The planned flow of participants through the stages of the study BCC, basic carbohydrate counting; ABC-ACC, advanced carbohydrate counting with an automated bolus calculator.

166x165mm (120 x 120 DPI)

# BMJ Open

**The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study): study protocol for a randomized, parallel, open-label, intervention study comparing different approaches to dietary self-management in patients with type 1 diabetes**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029859.R1
Article Type:	Protocol
Date Submitted by the Author:	26-Jun-2019
Complete List of Authors:	Ewers, Bettina; Steno Diabetes Center Copenhagen Vilsboell, Tina; Steno Diabetes Center Copenhagen; Kobenhavns Universitet, Department of Clinical Medicine, Faculty of Health and Medical Sciences Andersen, Henrik; Steno Diabetes Center Copenhagen Bruun, Jens; Steno Diabetes Center Aarhus; Aarhus University
<b>Primary Subject Heading</b>:	Nutrition and metabolism
Secondary Subject Heading:	Diabetes and endocrinology, Nutrition and metabolism
Keywords:	Randomized controlled trial, Type 1 diabetes, Carbohydrate counting, Basic carbohydrate counting, Advanced carbohydrate counting, Nutritional education

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study): study protocol for a randomized, parallel, open-label, intervention study comparing different approaches to dietary self-management in patients with type 1 diabetes

Bettina Ewers,<sup>1</sup> Tina Vilsboell,<sup>1,2</sup> Henrik Ullits Andersen,<sup>1</sup> Jens Meldgaard Bruun,<sup>3,4,5</sup>

<sup>1</sup>Steno Diabetes Center Copenhagen, Gentofte, Denmark.

<sup>2</sup>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.

<sup>3</sup>Steno Diabetes Center Aarhus, Aarhus, Denmark.

<sup>4</sup>Department of Clinical Medicine, University of Aarhus, Denmark.

<sup>5</sup>Department of Medicine, Randers Regional Hospital, Denmark.

**Correspondence to** Bettina Ewers, [bettina.ewers@regionh.dk](mailto:bettina.ewers@regionh.dk) or +45 30912997

## Abstract

**Introduction:** Clinical guidelines recommend that patients with type 1 diabetes (T1D) learn carbohydrate counting or similar methods to improve glycaemic control. Although, systematic educating in carbohydrate counting is still not offered as standard-of-care for all patients on multiple daily injections (MDI) therapy in outpatient diabetes clinics in Denmark. This may be due to the lack of evidence as to which educational methods are the most effective for training patients in carbohydrate counting. The objective of this study is to compare the effect of two different educational programs in carbohydrate counting with the usual dietary care on glycaemic control in patients with T1D.

**Methods and analysis:** The study is designed as a randomized, controlled trial with a parallel-group design. The total study duration is 12 months with data collection at baseline, 6 and 12 months. We plan to include 231 Danish adult patients with T1D. Participants will be randomized to one of three dietician-led interventions; 1) A program in basic carbohydrate counting, 2) A program in advanced carbohydrate counting including an automated bolus calculator or 3) Usual dietary care. The primary outcome is changes in glycated haemoglobin A1c (HbA1c) or mean amplitude of glycaemic excursions (MAGE) from baseline to end of the intervention period (week 24) between and within each of the three study groups. Other outcome measures include changes in other parameters of plasma glucose variability (e.g. time in range), body weight and composition, lipid profile, blood pressure, mathematical literacy skills, carbohydrate estimation accuracy, dietary intake, diet-related quality of life, perceived competencies in dietary management of diabetes and perceptions of an autonomy supportive dietician-led climate, physical activity and urinary biomarkers.

**Ethics and dissemination:** The protocol has been approved by the Ethics Committee of the Capital Region, Copenhagen, Denmark. Study findings will be disseminated widely through peer-reviewed publications and conference presentations.

**Registration:** The trial protocol is registered on ClinicalTrials.gov NCT03623113.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Strengths and limitations of this study

1. The study has a long-term follow-up and will provide knowledge on the effects of different levels of carbohydrate counting
2. The study applies well-documented measures of glycaemic control as effect-parameters
3. The results obtained have applicability beyond Denmark and has the potential to be included in the recommendations in future guidelines
4. A limitation is the lack of a dietary “untreated” control group, however; it would be unethical not to offer standard dietary care for patients with type 1 diabetes
5. The difference in the number of hours and type of dietary education and support between the groups may also influence the participants’ learning

## 1 Introduction

Carbohydrate is the nutrient in our diet with by far the highest impact on plasma glucose levels. The total amount of carbohydrates consumed in a meal is the major predictor of the postprandial glucose response. Thus, monitoring dietary intake of carbohydrates is important to control postprandial glucose fluctuations, which may lead to clinical benefits such as a reduction in glucose variability, an improvement of glycated haemoglobin A1c (HbA1c), and a reduction in diabetes-related complications.

Clinical guidelines in medical nutrition therapy recommend that patients with type 1 diabetes (T1D) learn carbohydrate counting or similar experience-based methods to improve glycaemic control (1-4). Two levels of carbohydrate counting have been defined internationally with different learning objectives and increasing complexity; a basic and an advanced level (5, 6). Basic carbohydrate counting (BCC) includes understanding of the relationship between food, physical activity, and plasma glucose levels with special attention on consistency in the timing, type, amount and distribution of carbohydrate-containing foods consumed. Advanced carbohydrate counting (ACC) is targeting the patient who masters BCC, who is on intensive insulin therapy and is prepared to learn how to adjust insulin according to carbohydrate intake. In the clinical guidelines and studies, the term “carbohydrate counting” is often used synonymously with ACC, while the sole effect of BCC on glycaemic control is largely unknown. Systematic reviews and meta-analyses of randomized controlled trials (RCTs) have shown that ACC can reduce HbA1c by up to 7 mmol/mol in adults with poorly controlled T1D (7-9). Despite this, systematic educating and training is still not offered routinely for patients on multiple daily insulin injections (MDI) therapy in outpatient clinics in Denmark. This may be due to the lack of evidence as to which educational methods are the most effective for training patients in carbohydrate counting in terms of supporting patients in implementation and ongoing adherence to the use of carbohydrate counting as a tool for meal planning in their daily life for improving glycaemic control.

Ideally, patients with T1D treated on MDI therapy need to be able to manage the following steps of calculation when using carbohydrate counting: 1) Correct calculation of the total carbohydrate content in each meal according to portion sizes of each carbohydrate containing food item (equal to BCC) and 2) Correct calculation of insulin dose according to the amount of carbohydrates to be consumed using a carbohydrate-to-insulin ratio, an insulin sensitivity factor, and the current and target plasma glucose (equal to ACC). In other words, patients with diabetes need to have sufficient mathematical literacy skills, including numeracy skills, to be able to practice the above-mentioned steps several times each day. Recent studies suggest that lower literacy and numeracy skills are associated with poorer portion size estimation, understanding of food labels, diabetes-related self-management abilities, diabetes control and increased body mass index (BMI) (10-16). Other studies have found that patients with diabetes frequently assess their intake of carbohydrates inaccurately and this has been associated with a poorer HbA1c (17-19). Particularly mixed meals, high-calorie foods, and larger portion sizes resulted in inaccurate carbohydrate estimation. One study also found that underestimation of carbohydrate-rich meals was associated with higher daily plasma glucose variability in adults with T1D (20). Thus, assessment of numeracy skills is highly relevant to ensure that a nutritional education programs address patients with low literacy and numeracy. This may be done by numeracy-focused educational exercises and materials or hands-on learning.

Recent years technological innovations including applications (apps) for smartphones have been introduced to reduce the complexity of carbohydrate counting and possibly compensate for poor numeracy skills. So far, no technological devices can replace the patients' self-estimations of the carbohydrate content in most meals e.g. in mixed meals (addressing step 1). RCTs have demonstrated that ACC supported by the use of automated bolus calculator (ABC) software to assist insulin dose decision making (addressing step 2) compared to



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

unassisted ACC significantly improves HbA1c and treatment satisfaction in patients with T1D treated with MDI (21-23). However, a recent exploratory study found that lower numeracy skills were associated with smaller reductions in HbA1c after a 12-month education program in ACC with no benefit from the use of an ABC compared to manual calculations (24). These findings support the need for more intensified dietary education in BCC before learning ACC. Additionally, the concept of ACC may not be useful in all patients with T1D on MDI therapy because of potential patient barriers, lack of motivation to learn the method, and low levels of education, literacy or numeracy skills. Other barriers include lack of appropriate learning environments to promote behavioural change and availability of trained dietitians to facilitate the learning process (25). In a study of patients with diabetes perceived competence was predicted by the degree to which the patients experienced the health-care climate to be autonomy supportive, and perceived competence at carrying out the treatment in turn predicted HbA1c (26). Group-based approaches with practised-focused dietary education compared to individual dietary counselling have been practiced in some settings but are under-investigated (27). In line with this we are currently carrying out a RCT based on this protocol.

## Aim

The aims are to examine the effectiveness of two different group-based dietitian-led practise-focused educational approaches for dietary self-management compared to the standard nutrition education on glycaemic control in patients with T1D. The BCC concept aims at improving carbohydrate counting accuracy and day-to-day consistency of carbohydrate intake (the BCC intervention) and the concept of ACC aim at improving prandial insulin dose accuracy using an automated bolus calculator (the ABC-ACC intervention).

## Methods and analysis

### Study design

The study is as a randomized controlled intervention trial with a parallel-group design (see figure 1).

For each participant the study duration is 48 months and includes up to seven visits at the study site (see figure 2). All participants will be instructed to maintain their habitual lifestyle in all other aspects than their diet, e.g. keeping the same level of physical activity during the study period. All participants will be instructed to follow their regular diabetes care in the hospital, which usually includes four yearly visits with a diabetologist (endocrinologist) and one yearly consultation with a diabetes nurse. Participants will be instructed not to receive any further dietary education during the study period. Close relatives can participate in the dietary education in all three study groups if the participant needs support to manage dietary changes.

The study flow is presented in figure 3. The study follows the guidelines of Standard Protocol Items for Randomized Trials (SPIRIT).

### Setting

The study will be carried out in the outpatient clinic at Steno Diabetes Center Copenhagen (SDCC) in Gentofte, Denmark.

### Recruitment and consent

As a temporary supplementary treatment initiative, SDCC offers courses in BCC and ABC-ACC for all patients with T1D treated in the capital region of Denmark. Participants for the current study will be recruited among patients signing up for these courses or patients directly referred to one of the courses or the study by

1  
2  
3  
4 85 a health care professional (diabetologist, diabetes nurse or dietitian) from SDCC or from a Steno Partner  
5 86 hospital in the capital region. A course administrator at SDCC will contact all interested or referred patients  
6 87 by telephone and provide information about the study. In addition, potential study participants will be recruited  
7 88 through information on sdcc.dk and other electronic media or patient-related networks. If the patient is  
8 89 interested in the study, the patient will receive the written patient information by mail or e-mail. If interested  
9 90 in study participation, the study investigator/study personnel will schedule a personal meeting for oral patient  
10 91 information, offering the possibility of bringing a confidant. The patient will be given time to discuss any  
11 92 questions and will be informed that he/she has at least 24 hours to decide on participation in the study. If the  
12 93 patient decides to participate in the study, the patient and the study investigator/study personnel will sign the  
13 94 written informed consent, and the investigator/study personnel will perform a screening. If all inclusion criteria  
14 95 are fulfilled and none of the exclusion criteria are met, the patient will be included in the study and randomised  
15 96 to one of three groups. Patients who decline to participate or do not meet the inclusion criteria will continue  
16 97 their usual care in an outpatient diabetes clinic and will be offered to participate on a BCC or ACC course if  
17 98 they still wish to do so. Participants will be informed that participation is voluntary, and that they may withdraw  
18 99 their consent at any time.  
20

#### 23 100 24 101 Inclusion criteria

25 102 Patients with T1D between 18-75 years of age with a diabetes duration above 12 months and with an initial  
26 103 HbA1c of 53-97 mmol/mol on MDI therapy with a basal-bolus insulin regime are eligible for the study.  
27 104

#### 29 105 Exclusion criteria

30 106 Patients are excluded if they have other types of diabetes than T1D, are practicing carbohydrate counting as  
31 107 judged by the investigator, have a low daily intake of carbohydrates (defined as below 25 E% or 100 g/day),  
32 108 have participated in a BCC group program within the last two years, use an insulin pump or plan to have an  
33 109 insulin pump within the study period, use split-mixed insulin therapy, use an open CGM or plan to have an  
34 110 open CGM within the study period, use an automated bolus calculator, have gastroparesis, have uncontrolled  
35 111 medical issues affecting the dietary intake as judged by the investigator or a medical expert. Women who are  
36 112 pregnant or breastfeeding or have plans of pregnancy within the study period are also excluded. Furthermore,  
37 113 patients who are either participating in other clinical studies or are unable to understand the informed consent  
38 114 and the study procedures will be excluded.  
39 115  
40 116

#### 43 116 Randomization

44 117 Participants eligible for inclusion in the study will be randomly allocated in a 1:1:1 ratio to one of the three  
45 118 groups (BCC, ABC-ACC or control) using a computer-generated randomization in the software program  
46 119 *REDCap*. The randomization is done by stratifying participants based on sex and HbA1c at baseline. The  
47 120 randomization is done in blocks in to order to ensure an equal number of participants in each group.  
48 121

#### 51 122 Intervention groups

52 123 The BCC program consists of two sessions of three hours and a follow-up group session of two hours. The  
53 124 BCC program uses trained dietitians following a planned curriculum which include experience-based learning  
54 125 with problem-solving exercises, hands-on activities, short theoretical presentations, discussions of  
55 126 motivational aspects and coping strategies. The BCC program integrates peer modelling, skills development,  
56 127 goal setting, observational learning and social support into the program content and activities. The training  
57 128 includes identifying carbohydrates in food, reading carbohydrate tables, calculating the carbohydrate content  
58 129  
59 130  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

from food labels, tables and apps and use of a personalized carbohydrate plan with guiding suggestions for daily intake of carbohydrates at meals based on 4-days of personal dietary recording performed before the program including plasma glucose measurements and prandial insulin dosages taken. An app (*Diabetes og Kulhydrattælling*®. The Danish Diabetes Association, Pragma soft A/S, available in Google Play® and AppStore®) will be introduced to support estimation and calculation of carbohydrates and assist in simple insulin dose determination if participants choose to consume more carbohydrates at a meal than suggested in their personal carbohydrate plan.

The ABC-ACC program consists of a 4-hour group session and two individual follow-up sessions (two 45-minute sessions). The program uses trained dietitians with supervision by a medical doctor and follows a planned curriculum. The ABC-ACC intervention is a group-based educational program based on the well-described BolusCal concept (28). The program includes fast training in BCC, ACC and bolus calculation using an automated bolus calculator (*mySugr Pro*®. Roche, available in Google Play® and AppStore®) taking insulin onboard, insulin sensitivity factor and differentiated carbohydrate-to-insulin ratios during the day into account. The carbohydrate-to-insulin ratios are based on 7-days of personal dietary recording including plasma glucose measurements and prandial insulin dosages taken. The ABC-ACC program contains theoretical and practical training. The teaching is based on theory and examples from everyday life with T1D and the educators help the participants with their specific diabetes-related problems and try to find appropriate practical solutions together with the participant.

#### Control group

Participants randomized to the control group receive current standard outpatient nutrition education in T1D. This includes individual guidance by a trained dietitian, with one initial 60 minutes dietary counselling session and two individual 30 minutes follow-up session. The individual guidance is based on the overall treatment goal and the defined personal dietary goals for behavioural change according to patient preferences. Dietary guidance includes topics such as carbohydrate sources (e.g. practicing glycaemic index and dietary fibre intake) and amounts of carbohydrates or more general dietary recommendations according to patient needs.

#### Data collection

All study data will be collected at the three visits with clinical examination (baseline, after 6 and 12 months). Data will be obtained from a self-reported patient questionnaire, electronic medical records and the physical examinations conducted by the study investigator or study personnel. All questionnaire data will be collected electronically using the software system *REDCap* according to local standards for research projects in the capital region of Denmark. In addition, all sources will be registered in this database. Data generated and stored for specific equipment (e.g. Dual-energy-X-ray absorptiometry (DXA) data stored in the DXA scanner software database), electronic medical data (blood and urine measurements, glucose- and lipid-lowering medicine), data from iPro®2 CGM using software from Medtronic (Northridge, CA, US) to download CGM measurements, dietary data on total energy and nutrients based calculations from the software system *Vitakost* will be added to the database in *REDCap* on an ongoing basis and at the end of study.

The primary outcome is the difference in mean HbA1c or MAGE from baseline to end of the intervention (week 24) between and within each of the three study groups (BCC, ABC-ACC and control).

A schematic overview of outcomes measurements is presented in table 1.

170 Table 1. Schematic overview of outcomes measured

Week no from start of intervention	-4 to -1	12	24	48
HbA1c	X	X	X	X
Plasma lipids	X		X	X
Body weight	X		X	X
Height	X			
Waist and hip circumference	X		X	X
Blood pressure	X		X	X
Blood samples, fasting	X		X	X
Urine samples for 4 days*	X		X	
Glucose variability (CGM) including PG diary for 6 days*	X		X	
Body composition (DXA)	X		X	
Prescribed lipid- and glucose lowering medication	X		X	X
F: Dietary registration for 4 days*	X		X	
Q: Diet-related quality of life	X		X	X
Q: Perceived Competencies in Diabetes	X		X	X
Q: Health-Care Climate	X		X	
Q: Carbohydrate estimation accuracy	X		X	X
Q: Mathematical literacy	X		X	X
Q: Demographic data	X			
Q: Physical activity	X		X	X

Abbreviations CGM=continuous glucose monitoring d=day; DXA=Dual-energy-X-ray absorptiometry; F=forms; PG=plasma glucose; Q=Questionnaire.

\*Measured in the days following the study visits.

Secondary outcomes are listed below:

*Clinical parameters:* Body weight, body composition (measured by DXA), waist and hip circumference blood pressure, type and dose of prescribed glucose- and lipid lowering medication, other parameters of plasma glucose variability including time in range (3.9-10.0 mmol/l), % time spent in hypoglycaemia (<3.9 mmol/l), % time spent in hyperglycaemia (e.g. >10.0 mmol/l) and standard deviation of mean plasma glucose assessed from CGM measurements.

*Blood and urine samples:* HbA1c (after 12 and 48 weeks), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, total cholesterol, free fatty acids and triglycerides, alanine aminotransferase (ALAT), urine albumin/creatinine ratio and urinary biomarkers based on three daily midstream urine spots collected for four days.

*Patient-reported outcomes:* Diet-related quality of life, perceived competencies in diabetes, health-care climate, carbohydrate estimation accuracy, mathematical literacy skills, physical activity and demographic questions. The six questionnaires used are:

*Diabetes diet-related quality of life questionnaire (DDRQOL):* The DDRQOL is a 31-item scale which has been validated in patients with diabetes (29). The scale is designed to determine the quantitative and qualitative satisfaction with diet and the degree of restriction of daily life and social life functions due to the dietary changes. A forward translation and cultural adaption of the DDRQOL was done by a Japanese-Danish interpreter with a background as a clinical dietitian and an expert panel of six clinical dietitians working with diabetes. This was followed by a pilot testing by 10 patients.

*Perceived Competencies in Diabetes Scale (PCS):* The PCS includes four items that reflect participants' feelings of competence about engaging in a healthier behaviour and participating in a nutritional education

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

program. Forward and backward linguistic translation from English to Danish has been done according to standard procedures in 2001 under the guidance of Professor Vibeke Zoffmann.

*Health-Care Climate Questionnaire (HCCQ)*: The HCCQ chosen in this study is a 5-item short form of the originally validated 15-item measure that assesses patients' perceptions of the degree to which dieticians are autonomy supportive versus controlling in providing dietary treatment.

*Carbohydrate photographic questionnaire (CPQ)*: The CPQ is an electronic questionnaire assessing diabetes patients' abilities to estimate portion sizes of 11 commonly eaten high-carbohydrate foods correctly. The CPQ has been developed and validated against real food in 87 patients with T1D. A manuscript of these study results has been submitted (Ewers et al, unpublished).

*Mathematical literacy questionnaire*: A 10-item test with modified questions from the nutrition domain of the *Diabetes Numeracy Test (DNT)* (30) was designed and feasibility tested to investigate mathematical literacy including numeracy skills (addition, subtraction, division and multiplication) which are essential for understanding numbers and applying mathematical skills in daily life e.g. for calculating carbohydrates.

*International Physical Activity Questionnaire Short Form (IPAQ SF)*: The Danish version of the IPAQ SF (31) will be used to assess changes in level of physical activity during the study period.

Self-reported demographic questions include level of education, occupation, marital status, household composition and yearly income.

*Dietary data*: Four days of weighed dietary food records collected at baseline and six months after baseline. Dietary records will be calculated using the software system *Vitakost* (Vitakost Aps, Kolding) where nutrient and energy calculations are based on the Danish national food database. The dietary food records are used to estimate total energy intake (kJ/d), intake of carbohydrates, protein and fat (g/day and g/meal), added sugar (g/d) and total dietary fibre intake (g/d).

*Baseline data (from the electronic medical record)*: type of diabetes, gender, age, smoking status, medical conditions, total number of visits at a diabetologist and diabetes nurse and dietician during the study period.

#### Data analysis plan

The trial is ongoing. The patient recruitment started in October 2018 and is expected to be completed by October 2021.

#### Sample size calculation

A power calculation was conducted based on the primary outcome measures HbA1c and MAGE. Allowing for an estimated drop-out rate of 20% and subgroup analyses the sample size was planned to include a total of 231 patients in the study (77 in each arm). This was based on a sample size calculation which suggested that including 64 participants in each of the study groups would give 80% power to detect a clinically meaningful difference in change in HbA1c of 3.5 mmol/mol between the BCC group versus the control group or the ABC-ACC group versus the control group with a 5% significance level using a two-sided test and an estimated standard deviation (SD) of 7 mmol/mol. This SD has previously been used for sample size calculations in ACC trials (21) and was similar to what was found in an evaluation of previous conducted BCC courses at SDCC on mean changes and SD of HbA1c after 6 months among completers with T1D (n=185). MAGE has only been used as an outcome measure of glucose variability in a few randomized controlled dietary intervention



1  
2  
3  
4 239 studies of patients with diabetes (32, 33) showing differences in changes in MAGE up to 4.8 mmol/l (SD: 1.0)  
5 240 after a 12-week carbohydrate counting intervention (32), but is regularly used in other clinical studies  
6 241 evaluating glucose variability . By including 77 participants in each study group we will have a power of 80%  
7 242 (alpha level of 0.05) in a two-sided test to detect a clinically meaningful difference in the change in MAGE  
8 243 during the intervention period (week 24) of  $\geq 0.35$  mmol/l (SD 0.7 mmol/l) between the study groups.  
9 244

## 10 244 11 12 245 **Statistical methods**

13 246 Analysis and reporting of the study results will follow the CONSORT (Consolidated Standards of Reporting  
14 247 Trials) guidelines for reporting parallel group randomised trials (34). Results will be presented as means (SD)  
15 248 for normally distributed variables and as medians (inter-quartile range) for non-normally distributed variables.  
16 249 One-way ANOVA will be used to compare baseline data between the three study groups for normal data and  
17 250 Kruskal-Wallis H test for non-normal data. Paired samples t-test will be used for within group comparison for  
18 251 normal data and Wilcoxon signed rank test for non-normal data. Mixed-effect models will be used to test  
19 252 differences in outcomes from baseline to follow-up to take repeated measurements into account. If model  
20 253 assumptions cannot be met even after logarithmic transformation, non-parametric tests will be used.  
21 254 Examinations of the relevant diagnostic plots, including QQ-plots, will be used to evaluate normality of the  
22 255 residuals.  
23 256

24 257 The baseline demographics as well as clinical and diabetes-related characteristics of the intervention and the  
25 258 control groups will be presented and compared. The average changes between baseline and week 24 and 48 in  
26 259 primary and secondary outcomes will be calculated for each of the three groups. Intention-to-treat (ITT)  
27 260 analysis will be performed as the primary analysis on all primary and secondary outcomes after the last  
28 261 participant has ended participation. Missing values will be handled with a last observation carried forward  
29 262 approach for ITT analysis with the use of the multiple imputation approach in a sensitivity analysis. Per-  
30 263 protocol (PP) analysis will only be performed in case of sensitivity testing. Metabolic patterns will be tested  
31 264 with multivariate statistics. Adjustment for relevant confounders will be performed including adjustment for  
32 265 the stratified variables. Heterogeneity in responsiveness to the interventions will be tested by dividing each  
33 266 intervention group into smaller groups based on data distribution (medians) or clinically meaningful cut-points.  
34 267 Two-sided tests will be used. *P* values of  $< 0.05$  are considered significant. The statistical programs SPSS and  
35 268 SAS will be used for data analysis.  
36 269

## 37 270 **Patient and public involvement**

38 271 Patients were involved in developing the educational content of the program in basic carbohydrate counting.  
39 272 Patients were not involved in setting the research questions or the outcome measures, nor were they involved  
40 273 in developing the study design. Information may be disseminated to the general public via any media coverage  
41 274 of study findings.  
42 275

## 43 276 44 277 **Ethics and dissemination**

45 278 The study will be conducted in accordance with the ethical principles in the Declaration of Helsinki and to the  
46 279 regulations for Good Clinical Practice (GCP) to the extent that this is relevant for non-medical studies. The  
47 280 study has been approved by the Ethics Committee of the Capital Region, Copenhagen (#H-18014897), has  
48 281 been approved for data storage by the Danish Data Protection Agency (journal no VD-2018-124, I-suite no  
49 282 6367) and has been registered at ClinicalTrials.gov (NCT03623113).  
50 283  
51 284

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

284 All health-related matters and sensitive personal data will be handled in accordance with the Danish “Act on  
285 Processing of Personal Data”. All health-related matters and sensitive personal data (blood test results etc.)  
286 will be depersonalized. All participants will be given a study number referring to their personal information,  
287 which will be stored securely and separately. Data will be stored in coded form for 10 years after last participant  
288 has attended the last visit, after which the data will be fully anonymised.

289  
290 Data is owned by the investigators who are responsible for publishing the results. Positive and negative as well  
291 as inconclusive study results will be published by the investigators in international peer-reviewed journals, and  
292 all co-authors must comply with the Vancouver rules. BE will be responsible for writing the first draft of the  
293 manuscript based on the main study results as a first author under guidance by TV and JMB. The study results  
294 will be presented at relevant national and international scientific conferences and meetings and will be  
295 published in international peer-reviewed scientific journals.

296  
297 Data sharing: Requests regarding dataset must be send to the corresponding author [bettina.ewers@regionh.dk](mailto:bettina.ewers@regionh.dk)

1  
2  
3  
4 300 **References**  
5  
6  
7

- 8 301 1. Kliniske retningslinjer for behandling af voksne med Type 1 diabetes. Sundhedsstyrelsen  
9 302 (Danish Health & Medicines Authority), Copenhagen; 2010.
- 10 303 2. Rammeplan for diætbehandling af type 1 diabetes Foreningen af kliniske diætister (The  
11 304 association of clinical dietitians); 2011.
- 12 305 3. Mann JI, De Leeuw I, Hermansen K, Karamanos B, Karlstrom B, Katsilambros N, et al.  
13 306 Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutrition,  
14 307 metabolism, and cardiovascular diseases : NMCD. 2004;14(6):373-94.
- 15 308 4. Sheard NF, Clark NG, Brand-Miller JC, Franz MJ, Pi-Sunyer FX, Mayer-Davis E, et al.  
16 309 Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the  
17 310 american diabetes association. *Diabetes Care*. 2004;27(9):2266-71.
- 18 311 5. Gillespie SJ, Kulkarni KD, Daly AE. Using carbohydrate counting in diabetes clinical  
19 312 practice. *J Am Diet Assoc*. 1998;98(8):897-905.
- 20 313 6. Kulkarni K. Carbohydrate Counting: A Practical Meal-Planning Option for People With  
21 314 Diabetes. *Clinical Diabetes*. 2005;23(5):120-2.
- 22 315 7. Bell KJ, Barclay AW, Petocz P, Colagiuri S, Brand-Miller JC. Efficacy of carbohydrate  
23 316 counting in type 1 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol*.  
24 317 2014;2(2):133-40.
- 25 318 8. Fu S, Li L, Deng S, Zan L, Liu Z. Effectiveness of advanced carbohydrate counting in type 1  
26 319 diabetes mellitus: a systematic review and meta-analysis. *Sci Rep*. 2016;6:37067.
- 27 320 9. Schmidt S, Schelde B, Norgaard K. Effects of advanced carbohydrate counting in patients  
28 321 with type 1 diabetes: a systematic review. *Diabet Med*. 2014;31(8):886-96.
- 29 322 10. Bowen ME, Cavanaugh KL, Wolff K, Davis D, Gregory B, Rothman RL. Numeracy and  
30 323 dietary intake in patients with type 2 diabetes. *Diabetes Educ*. 2013;39(2):240-7.
- 31 324 11. Cavanaugh K, Huizinga MM, Wallston KA, Gebretsadik T, Shintani A, Davis D, et al.  
32 325 Association of numeracy and diabetes control. *Ann Intern Med*. 2008;148(10):737-46.
- 33 326 12. Huizinga MM, Beech BM, Cavanaugh KL, Elasy TA, Rothman RL. Low numeracy skills are  
34 327 associated with higher BMI. *Obesity (Silver Spring)*. 2008;16(8):1966-8.
- 35 328 13. Huizinga MM, Carlisle AJ, Cavanaugh KL, Davis DL, Gregory RP, Schlundt DG, et al.  
36 329 Literacy, numeracy, and portion-size estimation skills. *Am J Prev Med*. 2009;36(4):324-8.
- 37 330 14. Marden S, Thomas PW, Sheppard ZA, Knott J, Lueddeke J, Kerr D. Poor numeracy skills are  
38 331 associated with glycaemic control in Type 1 diabetes. *Diabet Med*. 2012;29(5):662-9.
- 39 332 15. Rothman RL, DeWalt DA, Malone R, Bryant B, Shintani A, Crigler B, et al. Influence of  
40 333 patient literacy on the effectiveness of a primary care-based diabetes disease management program. *JAMA*.  
41 334 2004;292(14):1711-6.
- 42 335 16. Rothman RL, Housam R, Weiss H, Davis D, Gregory R, Gebretsadik T, et al. Patient  
43 336 understanding of food labels: the role of literacy and numeracy. *Am J Prev Med*. 2006;31(5):391-8.
- 44 337 17. Bishop FK, Maahs DM, Spiegel G, Owen D, Klingensmith GJ, Bortsov A, et al. The  
45 338 Carbohydrate Counting in Adolescents With Type 1 Diabetes (CCAT) Study. *Diabetes Spectrum*.  
46 339 2009;22(1):56-62.
- 47 340 18. Mehta SN, Quinn N, Volkening LK, Laffel LM. Impact of carbohydrate counting on glycemic  
48 341 control in children with type 1 diabetes. *Diabetes Care*. 2009;32(6):1014-6.
- 49 342 19. Smart CE, Ross K, Edge JA, King BR, McElduff P, Collins CE. Can children with Type 1  
50 343 diabetes and their caregivers estimate the carbohydrate content of meals and snacks? *Diabet Med*.  
51 344 2010;27(3):348-53.
- 52 345 20. Brazeau AS, Mircescu H, Desjardins K, Leroux C, Strychar I, Ekoe JM, et al. Carbohydrate  
53 346 counting accuracy and blood glucose variability in adults with type 1 diabetes. *Diabetes Res Clin Pract*.  
54 347 2013;99(1):19-23.
- 55 348 21. Hommel E, Schmidt S, Vistisen D, Neergaard K, Gribhild M, Almdal T, et al. Effects of  
56 349 advanced carbohydrate counting guided by an automated bolus calculator in Type 1 diabetes mellitus  
57 350 (StenoABC): a 12-month, randomized clinical trial. *Diabet Med*. 2017;34(5):708-15.  
58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

22. Schmidt S, Meldgaard M, Serifovski N, Storm C, Christensen TM, Gade-Rasmussen B, et al. Use of an automated bolus calculator in MDI-treated type 1 diabetes: the BolusCal Study, a randomized controlled pilot study. *Diabetes Care*. 2012;35(5):984-90.
23. Ziegler R, Cavan DA, Cranston I, Barnard K, Ryder J, Vogel C, et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. *Diabetes Care*. 2013;36(11):3613-9.
24. Schmidt S, Vistisen D, Almdal T, Hommel E, Norgaard K. Exploring factors influencing HbA1c and psychosocial outcomes in people with type 1 diabetes after training in advanced carbohydrate counting. *Diabetes Res Clin Pract*. 2017;130:61-6.
25. Kawamura T, Takamura C, Hirose M, Hashimoto T, Higashide T, Kashihara Y, et al. The factors affecting on estimation of carbohydrate content of meals in carbohydrate counting. *Clin Pediatr Endocrinol*. 2015;24(4):153-65.
26. Williams GC, Freedman ZR, Deci EL. Supporting autonomy to motivate patients with diabetes for glucose control. *Diabetes Care*. 1998;21(10):1644-51.
27. Toft U, Kristoffersen L, Ladelund S, Ovesen L, Lau C, Pisinger C, et al. The effect of adding group-based counselling to individual lifestyle counselling on changes in dietary intake. The Inter99 study--a randomized controlled trial. *Int J Behav Nutr Phys Act*. 2008;5:59.
28. Meldgaard M, Damm-Frydenberg C, Vesth U, Norgaard K, Schmidt S. Use of advanced carbohydrate counting and an automated bolus calculator in clinical practice: the BolusCal® training concept. *International Diabetes Nursing*. 2015;12:8-13.
29. Sato E, Suzukamo Y, Miyashita M, Kazuma K. Development of a diabetes diet-related quality-of-life scale. *Diabetes Care*. 2004;27(6):1271-5.
30. Huizinga MM, Elasy TA, Wallston KA, Cavanaugh K, Davis D, Gregory RP, et al. Development and validation of the Diabetes Numeracy Test (DNT). *BMC Health Serv Res*. 2008;8:96.
31. Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. *Int J Behav Nutr Phys Act*. 2011;8:115.
32. Bell KJ, Gray R, Munns D, Petocz P, Steil G, Howard G, et al. Clinical Application of the Food Insulin Index for Mealtime Insulin Dosing in Adults with Type 1 Diabetes: A Randomized Controlled Trial. *Diabetes Technol Ther*. 2016;18(4):218-25.
33. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, et al. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. *Am J Clin Nutr*. 2015;102(4):780-90.
34. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c869.

1  
2  
3  
4 389 **Authors' contributions:** BE conceived the original idea for this trial, planned the study design, performed  
5 the sample size calculations and wrote the first draft of the protocol manuscript. TV and JMB provided valuable  
6 390 input regarding trial design, planning and analytical considerations, and edited the first draft of the protocol  
7 391 manuscript. HUA has contributed intellectually to the protocol. All authors approved the final version of the  
8 392 clinical trial protocol. BE is the principle investigator and is responsible for correspondence with all authorities  
9 393 regarding the study and is responsible for the data collection (recruitment, screening and clinical study  
10 394 examinations), overall monitoring the trial and for conducting the statistical analyses. TV, JMB and HUA are  
11 395 supervisors and coinvestigators of this trial. Should any safety concerns arise during the conduct of the study  
12 396 these will be brought to the attention of HUA, TV and JMB by BE and will carefully reviewed.  
13 397  
14 398

15 399 **Funding statement:** This work was supported by The Beckett Foundation (grant number 17-2-0957), the  
16 400 Axel Muusfeldts Foundation (grant no 2017-856) and the Novo Nordisk Foundation (No assigned grant  
17 401 number) as part of a supplementary treatment initiative at SDCC in 2018-2020. Roche has provided voucher  
18 402 codes for free use of the bolus calculator "MySugr Pro" in the 12-month trial period for patients randomized  
19 403 to the ACC group in the study.  
20 404  
21 405  
22

23 406 **Competing interests:** None of the authors have financial relationships with organizations that might have  
24 407 an interest in the submitted work, or other relationships or activities that could appear to have influenced the  
25 408 submitted work.  
26 409  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

409 **Figure titles and legends (captions)**

410

411 **Figure 1.** Study design

412

413 **Figure 2.** Schematic diagram of the intervention

414

415 BCC, basic carbohydrate counting; ABC-ACC, advanced carbohydrate counting with an automated bolus  
416 calculator; BP, blood pressure; BW, body weight; CGM, Continuous Glucose Monitoring; DXA, dual-energy-  
417 X-ray absorptiometry; V, visit; WHC, waist-hip circumference.

418

419 **Figure 3.** Study flow diagram. The planned flow of participants through the stages of the study


420

421 BCC, basic carbohydrate counting; ABC-ACC, advanced carbohydrate counting with an automated bolus  
422 calculator.

423

424

425



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

**Screening visit**

- Patient information
- Informed written consent and screening

**V1 (week -4 to -1)**

- Baseline data collection
- Randomisation

**BCC education program**  
(n=77)

**ABC-ACC education program**  
(n=77)

**Standard dietary education**  
(n=77)

**V2 (week 0)**  
BCC group education session

**V2 (week 0)**  
ABC-ACC group education session

**V2 (week 0)**  
Individual dietary counselling

**V3 (week 2)**  
BCC group education session

**V3 (week 2)**  
ABC-ACC individual follow-up

**V3 (week 2)**  
Individual dietary follow-up

**V4 (week 12)**  
BCC group follow-up session

**V4 (week 12)**  
ABC-ACC individual follow-up

**V4 (week 12)**  
Individual dietary follow-up

**V5 (week 24)**

- Blood samples and BP
- Anthropometrics including DXA
- CGM and urine collection
- Questionnaires and registration forms

**V5 (week 24)**

- Blood samples and BP
- Anthropometrics including DXA
- CGM and urine collection
- Questionnaires and registration forms

**V5 (week 24)**

- Blood samples and BP
- Anthropometrics including DXA
- CGM and urine collection
- Questionnaires and registration forms

**V6 (week 48)**


- Blood samples
- BP, BW, WHC
- Questionnaires

**V6 (week 48)**

- Blood samples
- BP, BW, WHC
- Questionnaires

**V6 (week 48)**

- Blood samples
- BP, BW, WHC
- Questionnaires





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description for the DIET-CARB study	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	___p 1___
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	___p 1___
	2b	All items from the World Health Organization Trial Registration Data Set	___n/a___
Protocol version	3	Date and version identifier	___p 1___
Funding	4	Sources and types of financial, material, and other support	___p 40___
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	___p 2, 33___
	5b	Name and contact information for the trial sponsor	___n/a___
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	___n/a___
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	___n/a___

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention \_\_p 9-11\_\_

4

5

6 6b Explanation for choice of comparators \_\_\_\_\_

7

8 Objectives 7 Specific objectives or hypotheses \_\_p 12-13\_\_

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) \_\_p 15\_\_

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained \_\_p 17, 21\_\_

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) \_\_p 18\_\_

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered \_\_\_\_p 15-16\_

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) \_\_\_\_p 19\_\_

26

27 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) \_\_\_\_p 14\_\_

28

29

30 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial \_\_\_\_p 17\_\_

31

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended \_\_\_\_p 14\_\_

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) Table 1 page 22, Fig 2 page 26

41

42

43

44

45

46



1	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	___p 32___
2				
3				
4	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	___p 17-18___
5				

### 6 **Methods: Assignment of interventions (for controlled trials)**

#### 7 Allocation:

8				
9				
10	Sequence	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	___p 20___
11	generation			
12				
13				
14				
15				
16	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	___n/a___
17	concealment			
18	mechanism			
19				
20	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	___p 37___
21				
22				
23				
24	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	___n/a___
25				
26				
27		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	___n/a___
28				
29				
30				

### 31 **Methods: Data collection, management, and analysis**

32				
33	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	___p 23-25___
34	methods			
35				
36				
37				
38				
39		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	___p 19___
40				
41				
42				

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___p 33___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___p 32___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___p 32___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___p 32___
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___p 35___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___p 35-36___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___p 35___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___n/a___
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___p 35___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___p 36___
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	___p 20___
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	___p 30-31___
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	___p 33-34___
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	___p 40___
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	___p 37___
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	___n/a___
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	___p 38___
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	___p 33___
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	___n/a___
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendix 1, 2, 4, 5
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	___p 29-30___
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license. n/a, not relevant.  
 40  
 41  
 42

# BMJ Open

**The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study): study protocol for a randomized, parallel, open-label, intervention study comparing different approaches to dietary self-management in patients with type 1 diabetes**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-029859.R2
Article Type:	Protocol
Date Submitted by the Author:	08-Aug-2019
Complete List of Authors:	Ewers, Bettina; Steno Diabetes Center Copenhagen Vilsboell, Tina; Steno Diabetes Center Copenhagen; Kobenhavns Universitet, Department of Clinical Medicine, Faculty of Health and Medical Sciences Andersen, Henrik; Steno Diabetes Center Copenhagen Bruun, Jens; Steno Diabetes Center Aarhus; Aarhus University
<b>Primary Subject Heading</b>:	Nutrition and metabolism
Secondary Subject Heading:	Diabetes and endocrinology, Nutrition and metabolism
Keywords:	Randomized controlled trial, Type 1 diabetes, Carbohydrate counting, Basic carbohydrate counting, Advanced carbohydrate counting, Nutritional education

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study): study protocol for a  
5 randomized, parallel, open-label, intervention study comparing different approaches to dietary self-  
6 management in patients with type 1 diabetes  
7  
8  
9

10  
11  
12 Bettina Ewers,<sup>1</sup> Tina Vilsboell,<sup>1,2</sup> Henrik Ullits Andersen,<sup>1</sup> Jens Meldgaard Bruun,<sup>3,4,5</sup>  
13  
14  
15  
16

17 <sup>1</sup>Steno Diabetes Center Copenhagen, Gentofte, Denmark.

18  
19 <sup>2</sup>Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen,  
20 Denmark.  
21

22 <sup>3</sup>Steno Diabetes Center Aarhus, Aarhus, Denmark.

23  
24 <sup>4</sup>Department of Clinical Medicine, University of Aarhus, Denmark.

25  
26 <sup>5</sup>Department of Medicine, Randers Regional Hospital, Denmark.  
27  
28  
29  
30  
31  
32

33  
34 **Correspondence to** Bettina Ewers, Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, DK-2820  
35 Gentofte, [bettina.ewers@regionh.dk](mailto:bettina.ewers@regionh.dk) or +45 30912997.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Clinical guidelines recommend that patients with type 1 diabetes (T1D) learn carbohydrate counting or similar methods to improve glycaemic control. Although, systematic educating in carbohydrate counting is still not offered as standard-of-care for all patients on multiple daily injections (MDI) therapy in outpatient diabetes clinics in Denmark. This may be due to the lack of evidence as to which educational methods are the most effective for training patients in carbohydrate counting. The objective of this study is to compare the effect of two different educational programs in carbohydrate counting with the usual dietary care on glycaemic control in patients with T1D.

**Methods and analysis:** The study is designed as a randomized, controlled trial with a parallel-group design. The total study duration is 12 months with data collection at baseline, 6 and 12 months. We plan to include 231 Danish adult patients with T1D. Participants will be randomized to one of three dietician-led interventions; 1) A program in basic carbohydrate counting, 2) A program in advanced carbohydrate counting including an automated bolus calculator or 3) Usual dietary care. The primary outcome is changes in glycated haemoglobin A1c (HbA1c) or mean amplitude of glycaemic excursions (MAGE) from baseline to end of the intervention period (week 24) between and within each of the three study groups. Other outcome measures include changes in other parameters of plasma glucose variability (e.g. time in range), body weight and composition, lipid profile, blood pressure, mathematical literacy skills, carbohydrate estimation accuracy, dietary intake, diet-related quality of life, perceived competencies in dietary management of diabetes and perceptions of an autonomy supportive dietician-led climate, physical activity and urinary biomarkers.

**Ethics and dissemination:** The protocol has been approved by the Ethics Committee of the Capital Region, Copenhagen, Denmark. Study findings will be disseminated widely through peer-reviewed publications and conference presentations.

**Registration:** The trial protocol is registered on ClinicalTrials.gov NCT03623113.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Strengths and limitations of this study

1. The study has a long-term follow-up and will provide knowledge on the effects of different levels of carbohydrate counting
2. The study applies well-documented measures of glycaemic control as effect-parameters
3. The results obtained have applicability beyond Denmark and has the potential to be included in the recommendations in future guidelines
4. A limitation is the lack of a dietary “untreated” control group, however; it would be unethical not to offer standard dietary care for patients with T1D
5. The difference in the number of hours and type of dietary education and support between the groups may also influence the participants’ learning

## 1 Introduction

Carbohydrate is the nutrient in our diet with by far the highest impact on plasma glucose levels. The total amount of carbohydrates consumed in a meal is the major predictor of the postprandial glucose response. Thus, monitoring dietary intake of carbohydrates is important to control postprandial glucose fluctuations, which may lead to clinical benefits such as a reduction in glucose variability, an improvement of glycated haemoglobin A1c (HbA1c), and a reduction in diabetes-related complications.

Clinical guidelines in medical nutrition therapy recommend that patients with type 1 diabetes (T1D) learn carbohydrate counting or similar experience-based methods to improve glycaemic control (1-4). Two levels of carbohydrate counting have been defined internationally with different learning objectives and increasing complexity; a basic and an advanced level (5, 6). Basic carbohydrate counting (BCC) includes understanding of the relationship between food, physical activity, and plasma glucose levels with special attention on consistency in the timing, type, amount and distribution of carbohydrate-containing foods consumed. Advanced carbohydrate counting (ACC) is targeting the patient who masters BCC, who is on intensive insulin therapy and is prepared to learn how to adjust insulin according to carbohydrate intake. In the clinical guidelines and studies, the term “carbohydrate counting” is often used synonymously with ACC, while the sole effect of BCC on glycaemic control is largely unknown. Systematic reviews and meta-analyses of randomized controlled trials (RCTs) have shown that ACC can reduce HbA1c by up to 7 mmol/mol in adults with poorly controlled T1D (7-9). Despite this, systematic educating and training is still not offered routinely for patients on multiple daily insulin injections (MDI) therapy in outpatient clinics in Denmark. This may be due to the lack of evidence as to which educational methods are the most effective for training patients in carbohydrate counting in terms of supporting patients in implementation and ongoing adherence to the use of carbohydrate counting as a tool for meal planning in their daily life.

Ideally, patients with T1D treated on MDI therapy need to be able to manage the following steps of calculation when using carbohydrate counting: 1) Correct calculation of the total carbohydrate content in each meal according to portion sizes of each carbohydrate containing food item (equal to BCC) and 2) Correct calculation of insulin dose according to the amount of carbohydrates to be consumed using a carbohydrate-to-insulin ratio, an insulin sensitivity factor, and the current and target plasma glucose (equal to ACC). In other words, patients with diabetes need good mathematical literacy skills, including numeracy skills, to be able to practice the above-mentioned steps several times each day. Recent studies suggest that lower literacy and numeracy skills are associated with poorer portion size estimation, understanding of food labels, diabetes-related self-management abilities, diabetes control and increased body mass index (BMI) (10-16). Other studies have found that patients with diabetes frequently assess their intake of carbohydrates inaccurately and this has been associated with a poorer HbA1c (17-19). Particularly mixed meals, high-calorie foods, and larger portion sizes resulted in inaccurate carbohydrate estimation. One study also found that underestimation of carbohydrate-rich meals was associated with higher daily plasma glucose variability in adults with T1D (20). Thus, assessment of numeracy skills is highly relevant to ensure that a nutritional education programs address patients with low literacy and numeracy. This may be done by numeracy-focused educational exercises and materials or hands-on learning.

In recent years technological innovations including applications (apps) for smartphones have been introduced to reduce the complexity of carbohydrate counting and possibly compensate for poor numeracy skills. So far, no technological devices can replace the patients' self-estimations of the carbohydrate content in most meals e.g. in mixed meals (addressing step 1). RCTs have demonstrated that ACC supported by the use of automated bolus calculator (ABC) software to assist insulin dose decision making (addressing step 2) compared to



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

unassisted ACC significantly improves HbA1c and treatment satisfaction in patients with T1D treated with MDI (21-23). However, a recent exploratory study found that lower numeracy skills were associated with smaller reductions in HbA1c after a 12-month education program in ACC with no benefit from the use of an ABC compared to manual calculations (24). These findings support the need for more intensified dietary education in BCC before learning ACC. Additionally, the concept of ACC may not be useful in all patients with T1D on MDI therapy because of potential patient barriers, lack of motivation to learn the method, and low levels of education, literacy or numeracy skills. Other barriers include lack of appropriate learning environments to promote behavioural change and availability of trained dietitians to facilitate the learning process (25). In a study of patients with diabetes, perceived competence was predicted by the degree to which the patients experienced the health-care climate to be autonomy supportive, and perceived competence at carrying out the treatment in turn predicted HbA1c (26). Group-based approaches with practised-focused dietary education compared to individual dietary counselling have been practiced in some settings but are under-investigated (27). In line with this we are currently carrying out a RCT based on this protocol.

## Aim

The aims are to examine the effectiveness of two different group-based dietitian-led practise-focused educational approaches for dietary self-management compared to the standard nutrition education on glycaemic control in patients with T1D. The BCC concept aims at improving carbohydrate counting accuracy and day-to-day consistency of carbohydrate intake (the BCC intervention) and the concept of ACC aim at improving prandial insulin dose accuracy using an automated bolus calculator (the ABC-ACC intervention).

## Methods and analysis

### Study design

The study is as a randomized controlled intervention trial with a parallel-group design (see figure 1). The study duration is 48 months for each participant and includes up to seven visits at the study site (see figure 2). All participants will be instructed to maintain their habitual lifestyle in all other aspects than their diet, e.g. keeping the same level of physical activity during the study period. All participants will be instructed to follow their regular diabetes care in the hospital, which usually includes four yearly visits with a diabetologist (endocrinologist) and one yearly consultation with a diabetes nurse. Participants will be instructed not to receive any further dietary education during the study period. Close relatives can participate in the dietary education in all three study groups if the participant needs support to manage dietary changes.

The study flow is presented in figure 3. The study follows the guidelines of Standard Protocol Items for Randomized Trials (SPIRIT).

### Setting

The study will be carried out in the outpatient diabetes clinic at Steno Diabetes Center Copenhagen (SDCC) in Gentofte, Denmark.

### Recruitment and consent

As a temporary supplementary treatment initiative, SDCC offers courses in BCC and ABC-ACC for all patients with T1D treated in the capital region of Denmark. Participants for the current study will be recruited among patients signing up for these courses or patients directly referred to one of the courses or the study by a health care professional (diabetologist, diabetes nurse or dietitian) from SDCC or from a Steno Partner

1  
2  
3  
4 86 hospital in the capital region. A course administrator at SDCC will contact all interested or referred patients  
5 87 by telephone and provide information about the study. In addition, potential study participants will be recruited  
6 88 through information on sdcc.dk and other electronic media or patient-related networks. If the patient is  
7 89 interested in the study, the patient will receive the written patient information by mail or e-mail. If interested  
8 90 in study participation, the study investigator/study personnel will schedule a personal meeting for oral patient  
9 91 information, offering the possibility of bringing a confidant. The patient will be given time to discuss any  
10 92 questions and will be informed that he/she has at least 24 hours to decide on participation in the study. If the  
11 93 patient decides to participate in the study, the patient and the study investigator/study personnel will sign the  
12 94 written informed consent, and the investigator/study personnel will perform a screening. If all inclusion criteria  
13 95 are fulfilled and none of the exclusion criteria are met, the patient will be included in the study and randomized  
14 96 to one of three groups. Patients who decline to participate or do not meet the inclusion criteria will continue  
15 97 their usual care in an outpatient diabetes clinic and will be offered to participate on a BCC or ACC course if  
16 98 they still wish to do so. Participants will be informed that participation is voluntary, and that they may withdraw  
17 99 their consent at any time.  
20

#### 22 100 23 101 Inclusion criteria

24 102 Patients with T1D between 18-75 years of age with a diabetes duration above 12 months and with an initial  
25 103 HbA1c of 53-97 mmol/mol on MDI therapy with a basal-bolus insulin regime are eligible for the study.  
26 104

#### 28 105 Exclusion criteria

29 106 Patients are excluded if they have other types of diabetes than T1D, are practicing carbohydrate counting as  
30 107 judged by the investigator, have a low daily intake of carbohydrates (defined as below 25 E% or 100 g/day),  
31 108 have participated in a BCC group program within the last two years, use an insulin pump or plan to have an  
32 109 insulin pump within the study period, use split-mixed insulin therapy, use an automated bolus calculator, have  
33 110 gastroparesis, have uncontrolled medical issues affecting the dietary intake as judged by the investigator or a  
34 111 medical expert. Women who are pregnant or breastfeeding or have plans of pregnancy within the study period  
35 112 are also excluded. Furthermore, patients who are either participating in other clinical studies or are unable to  
36 113 understand the informed consent and the study procedures will be excluded.  
37 114  
38 115

#### 41 115 Randomization

42 116 Participants eligible for inclusion in the study will be randomly allocated in a 1:1:1 ratio to one of the three  
43 117 groups (BCC, ABC-ACC or control) using a computer-generated randomization in the software program  
44 118 *REDCap*. The randomization is done by stratifying participants based on sex and HbA1c at baseline. The  
45 119 randomization is done in blocks in to order to ensure an equal number of participants in each group.  
46 120  
47 121

#### 49 121 Intervention groups

50 122 The BCC program consists of two sessions of three hours and a follow-up group session of two hours. The  
51 123 BCC program uses trained dietitians following a planned curriculum which include experience-based learning  
52 124 with problem-solving exercises, hands-on activities, short theoretical presentations, discussions of  
53 125 motivational aspects and coping strategies. The BCC program integrates peer modelling, skills development,  
54 126 goal setting, observational learning and social support into the program content and activities. The training  
55 127 includes identifying carbohydrates in food, reading carbohydrate tables, calculating the carbohydrate content  
56 128 from food labels, tables and apps and use of a personalized carbohydrate plan with guiding suggestions for  
57 129 daily intake of carbohydrates at meals based on 4-days of personal dietary recording performed before the  
58 129  
59 130  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

program including plasma glucose measurements and prandial insulin dosages taken. An app (*Diabetes og Kulhydrattælling*®. The Danish Diabetes Association, Pragma soft A/S, available in Google Play® and AppStore®) will be introduced to support estimation and calculation of carbohydrates and assist in simple insulin dose determination if participants choose to consume more carbohydrates at a meal than suggested in their personal carbohydrate plan.

The ABC-ACC program consists of a 4-hour group session and two individual follow-up sessions (two 45-minute sessions). The program uses trained dietitians with supervision by a medical doctor and follows a planned curriculum. The ABC-ACC intervention is a group-based educational program based on the well-described BolusCal concept (28). The program includes fast training in BCC, ACC and bolus calculation using an automated bolus calculator (*mySugr Pro*®. Roche, available in Google Play® and AppStore®) taking insulin onboard, insulin sensitivity factor and differentiated carbohydrate-to-insulin ratios during the day into account. The carbohydrate-to-insulin ratios are based on 7-days of personal dietary recording including plasma glucose measurements and prandial insulin dosages taken. The ABC-ACC program contains theoretical and practical training. The teaching is based on theory and examples from everyday life with T1D and the educators help the participants with their specific diabetes-related problems and try to find appropriate practical solutions together with the participant.

#### Control group

Participants randomized to the control group receive current standard outpatient nutrition education in T1D. This includes individual guidance by a trained dietitian, with one initial 60 minutes dietary counselling session and two individual 30 minutes follow-up session. The individual guidance is based on the overall treatment goal and the defined personal dietary goals for behavioural change according to patient preferences. Dietary guidance includes topics such as carbohydrate sources (e.g. practicing glycaemic index and dietary fibre intake) and amounts of carbohydrates or more general dietary recommendations according to patient needs.

#### Delivery of dietary education

The educational program in both the standard treatment group and the intervention groups will be delivered by the same study dietitians. The dietitians have been trained by the PI (Bettina Ewers) in what to deliver in each study-arm according to the study protocol and in case of doubt, they will discuss each case with the PI to make sure that they provide the correct guidance to all participants. Data on which of the dietitians each participant has been exposed to during the trial is registered for later data analysis. Additionally, all study dietitians have an interest in providing the best possible dietary guidance irrespective of it being the standard treatment or the two intervention concepts being tested.

#### Data collection

All study data will be collected at the three visits with clinical examinations (baseline, after 6 and 12 months). Data will be obtained from a self-reported patient questionnaire, electronic medical records and the physical examinations conducted by the study investigator or study personnel. All questionnaire data will be collected electronically using the software system *REDCap* according to local standards for research projects in the capital region of Denmark. In addition, all sources will be registered in this database. Data generated and stored for specific equipment (e.g. Dual-energy-X-ray absorptiometry (DXA) data stored in the DXA scanner software database), electronic medical data (blood and urine measurements, glucose- and lipid-lowering medicine), data from iPro®2 CGM using software from Medtronic (Northridge, CA, US) to download CGM measurements, dietary data on total energy and nutrients based on calculations from the software system *Vitakost* will be added to the database in *REDCap* on an ongoing basis and at the end of study.

The primary outcome is the difference in mean HbA1c or MAGE from baseline to end of the intervention (week 24) between and within each of the three study groups (BCC, ABC-ACC and control). A schematic overview of outcomes measurements is presented in table 1.

Table 1. Schematic overview of outcomes measured

Week no from start of intervention	-4 to -1	12	24	48
HbA1c	X	X	X	X
Plasma lipids	X		X	X
Body weight	X		X	X
Height	X			
Waist and hip circumference	X		X	X
Blood pressure	X		X	X
Blood samples, fasting	X		X	X
Urine samples for 4 days*	X		X	
Glucose variability (CGM) including PG diary for 6 days*	X		X	
Body composition (DXA)	X		X	
Prescribed lipid- and glucose lowering medication	X		X	X
F: Dietary registration for 4 days*	X		X	
Q: Diet-related quality of life	X		X	X
Q: Perceived Competencies in Diabetes	X		X	X
Q: Health-Care Climate	X		X	
Q: Carbohydrate estimation accuracy	X		X	X
Q: Mathematical literacy	X		X	X
Q: Demographic data	X			
Q: Physical activity	X		X	X
Abbreviations CGM=continuous glucose monitoring d=day; DXA=Dual-energy-X-ray absorptiometry; F=forms; PG=plasma glucose; Q=Questionnaire.				

\*Measured in the days following the study visits.

Secondary outcomes are listed below:

**Clinical parameters:** Body weight, body composition (measured by DXA), waist and hip circumference, blood pressure, type and dose of prescribed glucose- and lipid lowering medication, other parameters of plasma glucose variability including time in range (3.9-10.0 mmol/l), % time spent in hypoglycaemia (<3.9 mmol/l), % time spent in hyperglycaemia (e.g. >10.0 mmol/l) and standard deviation of mean plasma glucose assessed from CGM measurements.

**Blood and urine samples:** HbA1c (after 12 and 48 weeks), plasma lipids (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, very low-density lipoprotein cholesterol, total cholesterol, free fatty acids and triglycerides), alanine aminotransferase (ALAT), urine albumin/creatinine ratio and urinary biomarkers based on three daily midstream urine spots collected for four days.

**Patient-reported outcomes:** Diet-related quality of life, perceived competencies in diabetes, health-care climate, carbohydrate estimation accuracy, mathematical literacy skills, physical activity and demographic questions. The six questionnaires used are:

**Diabetes diet-related quality of life questionnaire (DDRQOL):** The DDRQOL is a 31-item scale which has been validated in patients with diabetes (29). The scale is designed to determine the quantitative and qualitative satisfaction with diet and the degree of restriction of daily life and social life functions due to the dietary

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

changes. A forward translation and cultural adaptation of the DDRQOL was done by a Japanese-Danish interpreter with a background as a clinical dietitian and an expert panel of six clinical dietitians working with diabetes. This was followed by a pilot testing by 10 patients with diabetes.

*Perceived Competencies in Diabetes Scale (PCS)*: The PCS includes four items that reflect participants' feelings of competence about engaging in a healthier behaviour and participating in a nutritional education program. Forward and backward linguistic translation from English to Danish has been done according to standard procedures in 2001 under the guidance of Professor Vibeke Zoffmann.

*Health-Care Climate Questionnaire (HCCQ)*: The HCCQ chosen in this study is a 5-item short form of the originally validated 15-item measure that assesses patients' perceptions of the degree to which dietitians are autonomy supportive versus controlling in providing dietary treatment.

*Carbohydrate photographic questionnaire (CPQ)*: The CPQ is an electronic questionnaire assessing diabetes patients' abilities to estimate portion sizes of 11 commonly eaten high-carbohydrate foods correctly. The CPQ has been developed and validated against real food in 87 patients with T1D. A manuscript of these study results has been submitted (Ewers et al, unpublished).

*Mathematical literacy questionnaire*: A 10-item test with modified questions from the nutrition domain of the *Diabetes Numeracy Test (DNT)* (30) was designed and feasibility tested to investigate mathematical literacy including numeracy skills (addition, subtraction, division and multiplication) which are essential for understanding numbers and applying mathematical skills in daily life e.g. for calculating carbohydrates.

*International Physical Activity Questionnaire Short Form (IPAQ SF)*: The Danish version of the IPAQ SF (31) will be used to assess changes in level of physical activity during the study period.

Self-reported demographic questions include level of education, occupation, marital status, household composition and yearly income.

*Dietary data*: Four days of weighed dietary food records collected at baseline and six months after baseline. Dietary records will be calculated using the software system *Vitakost* (Vitakost Aps, Kolding) where nutrient and energy calculations are based on the Danish national food database. The dietary food records are used to estimate total energy intake (kJ/d), intake of carbohydrates, protein and fat (g/day and g/meal), added sugar (g/d) and total dietary fibre intake (g/d). The dietitian performing the analysis of the food records only have access to the study ID number and participant initials.

*Baseline data (from the electronic medical record)*: type of diabetes, diabetes duration, use of an open CGM, use of Freestyle Libre, gender, age, smoking status, medical conditions, total number of visits at a diabetologist and diabetes nurse and dietitian during the study period.

#### Data analysis plan

The trial is ongoing. The patient recruitment started in October 2018 and is expected to be completed by October 2021.

#### Sample size calculation

A power calculation was conducted based on the primary outcome measures HbA1c and MAGE. Allowing for an estimated drop-out rate of 20% and subgroup analyses the sample size was planned to include a total of



231 patients in the study (77 in each arm). This was based on a sample size calculation which suggested that including 64 participants in each of the study groups would give 80% power to detect a clinically meaningful difference in change in HbA1c of 3.5 mmol/mol between the BCC group versus the control group or the ABC-ACC group versus the control group with a 5% significance level using a two-sided test and an estimated standard deviation (SD) of 7 mmol/mol. This SD has previously been used for sample size calculations in ACC trials (21) and was similar to what was found in an evaluation of previous conducted BCC courses at SDCC on mean changes and SD of HbA1c after 6 months among completers with T1D (n=185). MAGE has only been used as an outcome measure of glucose variability in a few randomized controlled dietary intervention studies of patients with diabetes (32, 33) showing differences in changes in MAGE up to 4.8 mmol/l (SD: 1.0) after a 12-week carbohydrate counting intervention (32), but is regularly used in other clinical studies evaluating glucose variability. By including 77 participants in each study group we will have a power of 80% (alpha level of 0.05) in a two-sided test to detect a clinically meaningful difference in the change in MAGE during the intervention period (week 24) of  $\geq 0.35$  mmol/l (SD 0.7 mmol/l) between the study groups.

### Statistical methods

Analysis and reporting of the study results will follow the CONSORT (Consolidated Standards of Reporting Trials) guidelines for reporting parallel group randomized trials (34). Results will be presented as means (SD) for normally distributed variables and as medians (inter-quartile range) for non-normally distributed variables. One-way ANOVA will be used to compare baseline data between the three study groups for normal data and Kruskal-Wallis H test for non-normal data. Paired samples t-test will be used for within group comparison for normal data and Wilcoxon signed rank test for non-normal data. Mixed-effect models will be used to test differences in outcomes from baseline to follow-up to take repeated measurements into account. If model assumptions cannot be met even after logarithmic transformation, non-parametric tests will be used. Examinations of the relevant diagnostic plots, including QQ-plots, will be used to evaluate normality of the residuals.

The baseline demographics as well as clinical and diabetes-related characteristics of the intervention and the control groups will be presented and compared. The average changes between baseline and week 24 and 48 in primary and secondary outcomes will be calculated for each of the three groups. Intention-to-treat (ITT) analysis will be performed as the primary analysis on all primary and secondary outcomes after the last participant has ended participation. Missing values will be handled with a last observation carried forward approach for ITT analysis with the use of the multiple imputation approach in a sensitivity analysis. Per-protocol (PP) analysis will only be performed in case of sensitivity testing. Metabolic patterns will be tested with multivariate statistics. Adjustment for relevant confounders will be performed including adjustment for the stratified variables. Heterogeneity in responsiveness to the interventions will be tested by dividing each intervention group into smaller groups based on data distribution (medians) or clinically meaningful cut-points. Two-sided tests will be used. *P* values of  $< 0.05$  are considered significant. The statistical programs SPSS and SAS will be used for data analysis.

### Patient and public involvement

Patients were involved in developing the educational content of the BCC program. Patients were not involved in setting the research questions or the outcome measures, nor were they involved in developing the study design. Information may be disseminated to the public via any media coverage of study findings.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### **Ethics and dissemination**

The study will be conducted in accordance with the ethical principles in the Declaration of Helsinki and to the regulations for Good Clinical Practice (GCP) to the extent that this is relevant for non-medical studies. The study has been approved by the Ethics Committee of the Capital Region, Copenhagen (#H-18014897), has been approved for data storage by the Danish Data Protection Agency (journal no VD-2018-124, I-suite no 6367) and has been registered at ClinicalTrials.gov (NCT03623113).

All health-related matters and sensitive personal data will be handled in accordance with the Danish “Act on Processing of Personal Data”. All health-related matters and sensitive personal data (blood test results etc.) will be depersonalized. All participants will be given a study number referring to their personal information, which will be stored securely and separately. Data will be stored in coded form for 10 years after last participant has attended the last visit, after which the data will be fully anonymised.

Data is owned by the investigators who are responsible for publishing the results. Positive and negative as well as inconclusive study results will be published by the investigators in international peer-reviewed journals, and all co-authors must comply with the Vancouver rules. BE will be responsible for writing the first draft of the manuscript based on the main study results as a first author under guidance by TV and JMB. The study results will be presented at relevant national and international scientific conferences and meetings and will be published in international peer-reviewed scientific journals.

Data sharing: Requests regarding dataset must be send to the corresponding author [bettina.ewers@regionh.dk](mailto:bettina.ewers@regionh.dk)

1  
2  
3  
4 310 **References**  
5  
6  
7

- 8 311 1. Kliniske retningslinjer for behandling af voksne med Type 1 diabetes. Sundhedsstyrelsen  
9 312 (Danish Health & Medicines Authority), Copenhagen; 2010.
- 10 313 2. Rammeplan for diætbehandling af type 1 diabetes Foreningen af kliniske diætister (The  
11 314 association of clinical dietitians); 2011.
- 12 315 3. Mann JI, De Leeuw I, Hermansen K, Karamanos B, Karlstrom B, Katsilambros N, et al.  
13 316 Evidence-based nutritional approaches to the treatment and prevention of diabetes mellitus. Nutrition,  
14 317 metabolism, and cardiovascular diseases : NMCD. 2004;14(6):373-94.
- 15 318 4. Sheard NF, Clark NG, Brand-Miller JC, Franz MJ, Pi-Sunyer FX, Mayer-Davis E, et al.  
16 319 Dietary carbohydrate (amount and type) in the prevention and management of diabetes: a statement by the  
17 320 american diabetes association. *Diabetes Care*. 2004;27(9):2266-71.
- 18 321 5. Gillespie SJ, Kulkarni KD, Daly AE. Using carbohydrate counting in diabetes clinical  
19 322 practice. *J Am Diet Assoc*. 1998;98(8):897-905.
- 20 323 6. Kulkarni K. Carbohydrate Counting: A Practical Meal-Planning Option for People With  
21 324 Diabetes. *Clinical Diabetes*. 2005;23(5):120-2.
- 22 325 7. Bell KJ, Barclay AW, Petocz P, Colagiuri S, Brand-Miller JC. Efficacy of carbohydrate  
23 326 counting in type 1 diabetes: a systematic review and meta-analysis. *Lancet Diabetes Endocrinol*.  
24 327 2014;2(2):133-40.
- 25 328 8. Fu S, Li L, Deng S, Zan L, Liu Z. Effectiveness of advanced carbohydrate counting in type 1  
26 329 diabetes mellitus: a systematic review and meta-analysis. *Sci Rep*. 2016;6:37067.
- 27 330 9. Schmidt S, Schelde B, Norgaard K. Effects of advanced carbohydrate counting in patients  
28 331 with type 1 diabetes: a systematic review. *Diabet Med*. 2014;31(8):886-96.
- 29 332 10. Bowen ME, Cavanaugh KL, Wolff K, Davis D, Gregory B, Rothman RL. Numeracy and  
30 333 dietary intake in patients with type 2 diabetes. *Diabetes Educ*. 2013;39(2):240-7.
- 31 334 11. Cavanaugh K, Huizinga MM, Wallston KA, Gebretsadik T, Shintani A, Davis D, et al.  
32 335 Association of numeracy and diabetes control. *Ann Intern Med*. 2008;148(10):737-46.
- 33 336 12. Huizinga MM, Beech BM, Cavanaugh KL, Elasy TA, Rothman RL. Low numeracy skills are  
34 337 associated with higher BMI. *Obesity (Silver Spring)*. 2008;16(8):1966-8.
- 35 338 13. Huizinga MM, Carlisle AJ, Cavanaugh KL, Davis DL, Gregory RP, Schlundt DG, et al.  
36 339 Literacy, numeracy, and portion-size estimation skills. *Am J Prev Med*. 2009;36(4):324-8.
- 37 340 14. Marden S, Thomas PW, Sheppard ZA, Knott J, Lueddeke J, Kerr D. Poor numeracy skills are  
38 341 associated with glycaemic control in Type 1 diabetes. *Diabet Med*. 2012;29(5):662-9.
- 39 342 15. Rothman RL, DeWalt DA, Malone R, Bryant B, Shintani A, Crigler B, et al. Influence of  
40 343 patient literacy on the effectiveness of a primary care-based diabetes disease management program. *JAMA*.  
41 344 2004;292(14):1711-6.
- 42 345 16. Rothman RL, Housam R, Weiss H, Davis D, Gregory R, Gebretsadik T, et al. Patient  
43 346 understanding of food labels: the role of literacy and numeracy. *Am J Prev Med*. 2006;31(5):391-8.
- 44 347 17. Bishop FK, Maahs DM, Spiegel G, Owen D, Klingensmith GJ, Bortsov A, et al. The  
45 348 Carbohydrate Counting in Adolescents With Type 1 Diabetes (CCAT) Study. *Diabetes Spectrum*.  
46 349 2009;22(1):56-62.
- 47 350 18. Mehta SN, Quinn N, Volkening LK, Laffel LM. Impact of carbohydrate counting on glycemic  
48 351 control in children with type 1 diabetes. *Diabetes Care*. 2009;32(6):1014-6.
- 49 352 19. Smart CE, Ross K, Edge JA, King BR, McElduff P, Collins CE. Can children with Type 1  
50 353 diabetes and their caregivers estimate the carbohydrate content of meals and snacks? *Diabet Med*.  
51 354 2010;27(3):348-53.
- 52 355 20. Brazeau AS, Mircescu H, Desjardins K, Leroux C, Strychar I, Ekoe JM, et al. Carbohydrate  
53 356 counting accuracy and blood glucose variability in adults with type 1 diabetes. *Diabetes Res Clin Pract*.  
54 357 2013;99(1):19-23.
- 55 358 21. Hommel E, Schmidt S, Vistisen D, Neergaard K, Gribhild M, Almdal T, et al. Effects of  
56 359 advanced carbohydrate counting guided by an automated bolus calculator in Type 1 diabetes mellitus  
57 360 (StenoABC): a 12-month, randomized clinical trial. *Diabet Med*. 2017;34(5):708-15.
- 58  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

22. Schmidt S, Meldgaard M, Serifovski N, Storm C, Christensen TM, Gade-Rasmussen B, et al. Use of an automated bolus calculator in MDI-treated type 1 diabetes: the BolusCal Study, a randomized controlled pilot study. *Diabetes Care*. 2012;35(5):984-90.
23. Ziegler R, Cavan DA, Cranston I, Barnard K, Ryder J, Vogel C, et al. Use of an insulin bolus advisor improves glycemic control in multiple daily insulin injection (MDI) therapy patients with suboptimal glycemic control: first results from the ABACUS trial. *Diabetes Care*. 2013;36(11):3613-9.
24. Schmidt S, Vistisen D, Almdal T, Hommel E, Norgaard K. Exploring factors influencing HbA1c and psychosocial outcomes in people with type 1 diabetes after training in advanced carbohydrate counting. *Diabetes Res Clin Pract*. 2017;130:61-6.
25. Kawamura T, Takamura C, Hirose M, Hashimoto T, Higashide T, Kashihara Y, et al. The factors affecting on estimation of carbohydrate content of meals in carbohydrate counting. *Clin Pediatr Endocrinol*. 2015;24(4):153-65.
26. Williams GC, Freedman ZR, Deci EL. Supporting autonomy to motivate patients with diabetes for glucose control. *Diabetes Care*. 1998;21(10):1644-51.
27. Toft U, Kristoffersen L, Ladelund S, Ovesen L, Lau C, Pisinger C, et al. The effect of adding group-based counselling to individual lifestyle counselling on changes in dietary intake. The Inter99 study--a randomized controlled trial. *Int J Behav Nutr Phys Act*. 2008;5:59.
28. Meldgaard M, Damm-Frydenberg C, Vesth U, Norgaard K, Schmidt S. Use of advanced carbohydrate counting and an automated bolus calculator in clinical practice: the BolusCal® training concept. *International Diabetes Nursing*. 2015;12:8-13.
29. Sato E, Suzukamo Y, Miyashita M, Kazuma K. Development of a diabetes diet-related quality-of-life scale. *Diabetes Care*. 2004;27(6):1271-5.
30. Huizinga MM, Elasy TA, Wallston KA, Cavanaugh K, Davis D, Gregory RP, et al. Development and validation of the Diabetes Numeracy Test (DNT). *BMC Health Serv Res*. 2008;8:96.
31. Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. *Int J Behav Nutr Phys Act*. 2011;8:115.
32. Bell KJ, Gray R, Munns D, Petocz P, Steil G, Howard G, et al. Clinical Application of the Food Insulin Index for Mealtime Insulin Dosing in Adults with Type 1 Diabetes: A Randomized Controlled Trial. *Diabetes Technol Ther*. 2016;18(4):218-25.
33. Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, et al. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. *Am J Clin Nutr*. 2015;102(4):780-90.
34. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340:c869.

1  
2  
3  
4 399 **Authors' contributions:** BE conceived the original idea for this trial, planned the study design, performed  
5 400 the sample size calculations and wrote the first draft of the protocol manuscript. TV and JMB provided valuable  
6 401 input regarding trial design, planning and analytical considerations, and edited the first draft of the protocol  
7 402 manuscript. HUA has contributed intellectually to the protocol. All authors approved the final version of the  
8 403 clinical trial protocol. BE is the principle investigator and is responsible for correspondence with all authorities  
9 404 regarding the study and is responsible for the data collection (recruitment, screening and clinical study  
10 405 examinations), overall monitoring the trial and for conducting the statistical analyses. TV, JMB and HUA are  
11 406 supervisors and coinvestigators of this trial. Should any safety concerns arise during the conduct of the study  
12 407 these will be brought to the attention of HUA, TV and JMB by BE and will carefully reviewed.  
13 408

14 409 **Funding statement:** This work was supported by The Beckett Foundation (grant number 17-2-0957), the  
15 410 Axel Muusfeldts Foundation (grant no 2017-856) and the Novo Nordisk Foundation (no assigned grant  
16 411 number) as part of a supplementary treatment initiative at SDCC in 2018-2020. Roche has provided voucher  
17 412 codes for free use of the bolus calculator "MySugr Pro" in the 12-month trial period for patients randomized  
18 413 to the ACC group in the study.  
19 414

20 415 **Competing interests:** None of the authors have financial relationships with organizations that might have  
21 416 an interest in the submitted work, or other relationships or activities that could appear to have influenced the  
22 417 submitted work.  
23 418

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

419 **Figure titles and legends (captions)**

420

421 **Figure 1.** Study design

422

423 **Figure 2.** Schematic diagram of the intervention

424

425 BCC, basic carbohydrate counting; ABC-ACC, advanced carbohydrate counting with an automated bolus  
426 calculator; BP, blood pressure; BW, body weight; CGM, Continuous Glucose Monitoring; DXA, dual-energy-  
427 X-ray absorptiometry; V, visit; WHC, waist-hip circumference.

428

429 **Figure 3.** Study flow diagram. The planned flow of participants through the stages of the study


430

431 BCC, basic carbohydrate counting; ABC-ACC, advanced carbohydrate counting with an automated bolus  
432 calculator.

433

434

435



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

**Screening visit**

- Patient information
- Informed written consent and screening

**V1 (week -4 to -1)**

- Baseline data collection
- Randomisation

**BCC education program**  
(n=77)

**ABC-ACC education program**  
(n=77)

**Standard dietary education**  
(n=77)

**V2 (week 0)**  
BCC group education session

**V2 (week 0)**  
ABC-ACC group education session

**V2 (week 0)**  
Individual dietary counselling

**V3 (week 2)**  
BCC group education session

**V3 (week 2)**  
ABC-ACC individual follow-up

**V3 (week 2)**  
Individual dietary follow-up

**V4 (week 12)**  
BCC group follow-up session

**V4 (week 12)**  
ABC-ACC individual follow-up

**V4 (week 12)**  
Individual dietary follow-up

**V5 (week 24)**

- Blood samples and BP
- Anthropometrics including DXA
- CGM and urine collection
- Questionnaires and registration forms

**V5 (week 24)**

- Blood samples and BP
- Anthropometrics including DXA
- CGM and urine collection
- Questionnaires and registration forms

**V5 (week 24)**

- Blood samples and BP
- Anthropometrics including DXA
- CGM and urine collection
- Questionnaires and registration forms

**V6 (week 48)**

- Blood samples
- BP, BW, WHC
- Questionnaires


**V6 (week 48)**

- Blood samples
- BP, BW, WHC
- Questionnaires

**V6 (week 48)**

- Blood samples
- BP, BW, WHC
- Questionnaires

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description for the DIET-CARB study	Addressed on page number
<b>Administrative information</b>			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	____p 1__
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	____p 1__
	2b	All items from the World Health Organization Trial Registration Data Set	____n/a__
Protocol version	3	Date and version identifier	____p 1__
Funding	4	Sources and types of financial, material, and other support	____p 40__
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	____p 2, 33__
	5b	Name and contact information for the trial sponsor	____n/a__
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	____n/a__
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	____n/a__

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention \_\_p 9-11\_\_

4

5

6 6b Explanation for choice of comparators \_\_\_\_\_

7

8 Objectives 7 Specific objectives or hypotheses \_\_p 12-13\_\_

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) \_\_p 15\_\_

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained \_\_p 17, 21\_\_

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) \_\_p 18\_\_

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered \_\_\_\_p 15-16\_

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) \_\_\_\_p 19\_\_

26

27 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) \_\_\_\_p 14\_\_

28

29

30 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial \_\_\_\_p 17\_\_

31

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended \_\_\_\_p 14\_\_

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) Table 1 page 22, Fig 2 page 26

41

42

43

44

45

46



1 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including \_\_\_p 32\_\_\_  
 2 clinical and statistical assumptions supporting any sample size calculations

3  
 4 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size \_\_\_p 17-18\_\_\_  
 5

6 **Methods: Assignment of interventions (for controlled trials)**

7  
 8 Allocation:

9  
 10 Sequence 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any \_\_\_p 20\_\_\_  
 11 generation factors for stratification. To reduce predictability of a random sequence, details of any planned restriction  
 12 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants  
 13 or assign interventions  
 14  
 15

16 Allocation 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, \_\_\_n/a\_\_\_  
 17 concealment opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned  
 18 mechanism  
 19

20 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to \_\_\_p 37\_\_\_  
 21 interventions  
 22  
 23

24 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome \_\_\_n/a\_\_\_  
 25 assessors, data analysts), and how  
 26

27 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's \_\_\_n/a\_\_\_  
 28 allocated intervention during the trial  
 29  
 30

31 **Methods: Data collection, management, and analysis**

32  
 33 Data collection 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related \_\_\_p 23-25\_\_\_  
 34 methods processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of  
 35 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.  
 36 Reference to where data collection forms can be found, if not in the protocol  
 37  
 38

39 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be \_\_\_p 19\_\_\_  
 40 collected for participants who discontinue or deviate from intervention protocols  
 41  
 42

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	___p 33___
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___p 32___
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___p 32___
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___p 32___
11				
12				
13				
14	<b>Methods: Monitoring</b>			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___p 35___
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___p 35-36___
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___p 35___
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___n/a___
29				
30				
31				
32	<b>Ethics and dissemination</b>			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___p 35___
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___p 36___
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	___p 20___
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	___p 30-31___
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	___p 33-34___
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	___p 40___
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	___p 37___
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	___n/a___
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	___p 38___
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	___p 33___
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	___n/a___
27				
28				
29	<b>Appendices</b>			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	Appendix 1, 2, 4, 5
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	___p 29-30___
35				
36				

37 \*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.  
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons  
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license. n/a, not relevant.  
 40  
 41  
 42